Liposomal formulations and methods of using and preparing liposomal formulations
Liposome-encapsulated phosphorylated carbohydrates address the delivery challenges of CDG disorders by entering cells and supplying essential substrates to glycosylation pathways, offering a promising treatment for CDG-Ia and CDG type II.
Patent Information
- Application Number
- JP2021560323
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-29
- Filing Date
- 2020-03-27
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2040-03-27
AI Technical Summary
Current treatments for CDG disorders, particularly CDG-Ia and CDG type II, are ineffective due to the highly heterogeneous clinical phenotype and challenges in delivering phosphorylated carbohydrates like mannose-1-phosphate (Man-1-P) across cell membranes, which are degraded extracellularly and unable to enter the cell interior, leading to insufficient substrate supply for downstream enzymes.
Development of liposomes encapsulating phosphorylated carbohydrates, such as mannose-1-phosphate, using lipid particles that can enter the cell interior via the endocytic pathway, facilitating delivery to the cytosol and biochemical glycosylation pathways, thereby overcoming stability, cytotoxicity, and delivery efficiency issues.
The liposome-encapsulated phosphorylated carbohydrates effectively deliver therapeutic doses to the cell interior, providing a potential treatment for CDG disorders by bypassing enzymatic deficiencies and improving glycosylation processes.
Smart Images

Figure 0007583741000106 
Figure 0007583741000107 
Figure 0007583741000108
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 826,874, filed March 29, 2019, which is incorporated by reference in its entirety.
[0002] Field The present invention relates to compositions containing carbohydrates encapsulated in liposomes for delivery to the interior of cells, methods for delivering the encapsulated carbohydrates to the interior of cells, and methods of using such compositions to treat diseases and disorders, such as congenital defective glycosylation (CDG) disorders. For example, the present invention relates to methods for preparing carbohydrates and liposomes for pharmaceutical delivery to the interior of cells, the endoplasmic reticulum (ER), and the Golgi. [Background technology]
[0003] background Glycosylation, the enzymatic attachment of carbohydrates (glycans) to proteins and lipids, is the more common co-translational and post-translational modification (PTM) than any other PTM, as it applies to the majority of proteins synthesized in the rough endoplasmic reticulum (ER). Glycosylation plays a pivotal role in various biological processes of membrane and secreted proteins. In the ER, glycosylation acts as a quality control mechanism that defines protein structure and folding, directing export of properly folded proteins to the Golgi or targeting misfolded proteins for degradation. Glycan moieties may act as ligands for cell surface receptors to mediate cell binding or stimulate signaling pathways. Congenital disorders of glycosylation, also known as CDG syndromes, are a group of rare genetic disorders in which tissue proteins and / or lipids retain defective and / or absent glycosylation. These diseases are associated with numerous enzyme deficiencies and often cause severe, sometimes fatal, dysfunction of the nervous system, muscles, intestine, and several other organ systems.
[0004] Common clinical manifestations in children with CDG include hypotonia, growth retardation, failure to thrive, liver dysfunction, coagulopathy, hypothyroidism, esotropia, abnormal fat patterns and inverted nipples, hypoglycemia, seizures, cerebellar hypoplasia, and stroke-like episodes in developmentally delayed children. At older ages, in adolescence or adulthood, symptoms may include ataxia, cognitive impairment, absence of puberty in females, small testes in males, retinitis pigmentosa, scoliosis, joint contractures, and peripheral neuropathy.
[0005] CDG may be classified into two groups: CDG type I and CDG type II. CDG type I is characterized by defects in the initial step of N-linked protein glycosylation, i.e., the biosynthesis of dolichol pyrophosphate-linked oligosaccharides (DLOs) that originate in the ER, or the transfer of DLOs to asparagine residues of nascent polypeptides. In CDG type II, there is a defect in the further processing (synthetic or hydrolytic) of protein-linked glycans. Currently, 22 variants of CDG type I and 14 variants of type II have been identified. One of the most common subtypes of CDG is CDG-Ia (approximately 70% of all CDG cases), which is characterized by a loss or reduction of phosphomannomutase 2 (PMM) activity that results in defective or insufficient intracellular N-glycosylation (Jaeken et al. J. of Inherit. Met. Disease. 2008, 31: 669-672). PMM is responsible for the conversion of mannose-6-phosphate to mannose-1-phosphate.
[0006] Although several different approaches to developing a treatment for CDG have been explored, researchers continue to search for a suitable therapy or treatment to alleviate the disease itself. Existing treatments for symptoms include, for example, nutritional supplements, tube feeding, and a wide range of treatments that attempt to treat gastroesophageal reflux, persistent vomiting, growth retardation, ocular abnormalities, and hypothyroidism. Patients also require intravenous (IV) hydration and physical therapy for stroke-like episodes. Adults with orthopedic symptoms often require wheelchairs, mobility devices, and surgical treatment for scoliosis (Sparks et al., Disorders of Glycosylation Overview. 2005 In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews TM Seattle (WA): University of Washington, Seattle; 1993-2013).
[0007] Currently, CDG-Ib is one known CDG for which treatment is available, i.e. oral D-mannose administration is possible.However, such treatment may not be effective for treating CDG-Ia patients, and other CDG type I subtypes and CDG type II disease currently have limited treatment options.One of the reasons for the lack of established treatment for CDG-I disorder may be due to the excessive heterogeneous clinical phenotypes presented, which do not show direct correlation to PMM enzyme activity.
[0008] Patients suffering from reduced PMM activity have reduced production of mannose-1-phosphate (Man-1-P) associated with symptoms of multiple organ failure. To overcome PMM production deficiency, it is important to supply downstream enzymes with the required substrate (i.e., Man-1-P). However, delivery and maintenance of such a systemic supply of Man-1-P is problematic because extracellular enzymes in body fluids degrade Man-1-P when delivered externally by oral or intravenous administration. Another problem with exogenously delivered Man-1-P is that due to its high polarity, Man-1-P cannot enter the cell interior (i.e., cytosol) and therefore cannot treat the deficiency of PMM production.
[0009] Polar Man-1-P derivatives can be synthesized to make Man-1-P more cell-permeable (US Patent Application Publication No. 2009 / 0054353). However, this approach is still problematic because cell-permeable Man-1-P derivatives have been shown to be unstable in clinical use or to be cytotoxic via by-products of the Man-1-P derivatives (Eklund et al., Glycobiology 2005, 15: 1084-1093; Rutschow et al. Bioorg Med Chem 2002, 10: 4043-4049; and Hardre et al., Bioorg Med Chem Lett 2007, 17: 152-155).
[0010] Other potential therapies have focused on inhibiting mannose-6-phosphate (Man-6-P), the enzyme that catabolizes the precursor to Man-1-P, via inhibition of phosphomannose isomerase (PMI). This approach focuses on forcing the response toward optimizing homeostasis that could be biased toward the production of Man-6-P by the use of PMI inhibitors. However, these approaches are not effective as clinical treatment options due to their associated toxicity, off-target side effects, and poor selective tissue penetration. Another possible solution is to use a delivery vehicle (e.g., lipid particles) to encapsulate and deliver Man-1-P to the inside of cells (see WO 2015 / 053910). However, due to the generally high charge and polarity of phosphorylated carbohydrates, an optimal delivery vehicle must overcome the challenges of stability, phosphorylated carbohydrate loading rate and concentration, toxicity, and delivery efficiency. Thus, there is an unmet need for improved compositions and methods for delivering phosphorylated carbohydrates, such as Man-1-P and Man-6-P, to the interior of cells to treat disorders such as congenital glycosylation disorders (CDGs) in subjects (including, e.g., humans) in need of such treatment. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] US Patent Application Publication No. 2009 / 0054353 [Patent Document 2] International Publication No. 2015 / 053910 [Non-patent literature]
[0012] [Non-Patent Document 1] Jaeken et al. J. of Inherit. Met. Disease. 2008, 31: 669-672 [Non-Patent Document 2] Sparks et al., Disorders of Glycosylation Overview. 2005 In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviewsTM. Seattle (WA): University of Washington, Seattle; 1993-2013 [Non-Patent Document 3] Eklund et al., Glycobiology 2005, 15: 1084-1093 [Non-Patent Document 4] Rutschow et al. Bioorg Med Chem 2002, 10: 4043-4049 [Non-Patent Document 5] Hardre et al., Bioorg Med Chem Lett 2007, 17: 152-155 Summary of the Invention [Means for solving the problem]
[0013] overview The present disclosure satisfies the above-mentioned unmet need by providing compositions and kits including phosphorylated carbohydrates encapsulated by certain liposomes that address the problems of phosphorylated carbohydrate loading efficiency, cytotoxicity, and stability associated with either cell penetration or encapsulation of phosphorylated carbohydrates using lipid particles. Such phosphorylated carbohydrates may be endogenous carbohydrates, including, for example, mannose-1-phosphate. By utilizing the endocytosis pathway, these liposomes can enter the cell interior and deliver phosphorylated carbohydrates to the cytosol of the cell. This use of certain liposomes to encapsulate phosphorylated carbohydrates simultaneously promotes the ease of treatment and allows higher dosages of phosphorylated carbohydrates to reach the biochemical glycosylation pathway, with potentially easier administration. In some aspects, the present disclosure provides methods for preparing phosphorylated carbohydrates encapsulated by certain liposomes for pharmaceutical delivery to the cell interior, endoplasmic reticulum, and Golgi. The present disclosure provides phosphorylated carbohydrate replacement therapy for treating, but not limited to, CDG type I and CDG type II diseases.
[0014] The present disclosure also addresses the unmet need for effective treatment of diseases, such as CDG disease, as well as the challenges of delivering such therapeutics.In some aspects, the present disclosure provides a method for delivering phosphorylated carbohydrates, such as mannose-1-phosphate, to the cytosol of cells.Without being bound by any theory, it is believed that such a method for delivering phosphorylated carbohydrates (e.g., as part of a pharmaceutical) may avoid the action of genetically defective cytosol enzymes, namely phosphomannomutase (PMM) and phosphomannose isomerase (PMI), which are prevalent in CDG I disorders.
[0015] In some embodiments, the present disclosure provides: A liposome comprising: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); ii) (a) a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine; and C 10~28 and a fatty acid tail comprising an aliphatic chain; or (b) an acidic cholesterol ester, or a mixture of (a) and (b); one or more stabilizers selected from: iii) PEG conjugated to at least one phospholipid. A liposome comprising At least one endogenous phosphorylated carbohydrate wherein at least one endogenous phosphorylated carbohydrate is encapsulated in a liposome.
[0016] In some embodiments, at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). In some embodiments, one or more stabilizers include 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), or 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS). In some embodiments, DOPE is present at a concentration of up to 80 mol%. In some embodiments, the liposome further includes cholesterol.
[0017] In some embodiments, the present disclosure provides: A liposome comprising: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE); and ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0018] In some embodiments, the liposome further comprises PEG conjugated to at least one phospholipid. In some embodiments, the at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). In some embodiments, the liposome further comprises cholesterol.
[0019] In some embodiments, the at least one endogenous phosphorylated carbohydrate is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. In some embodiments, the at least one endogenous phosphorylated carbohydrate is a phosphorylated mannose. In some embodiments, the phosphorylated mannose is mannose-1-phosphate. In some embodiments, the phosphorylated mannose is mannose-6-phosphate. In some embodiments, the endogenous phosphorylated carbohydrate is present at a concentration of about 0.1 to 75 mM.
[0020] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a composition of any of the preceding embodiments and a pharma- ceutically acceptable carrier.
[0021] Other aspects of the present disclosure relate to kits containing the compositions of any of the preceding embodiments for use in any of the methods described herein.
[0022] Other aspects of the present disclosure relate to methods for delivering phosphorylated carbohydrates to a subject in need thereof by administering to the subject a composition of any of the preceding embodiments, hi some embodiments, the composition is administered orally, topically, dermally, nasally, intravenously, intramuscularly, intraperitoneally, intracerebrospinal, intracranially, intrathecally, subcutaneously, intra-articularly, or intrasynovially, intraspinally.
[0023] Another aspect of the present disclosure relates to a method for delivering phosphorylated carbohydrates to the interior of a cell of a subject in need thereof by administering to the subject a composition of any of the preceding embodiments, hi some embodiments, the composition is administered orally, topically, dermally, nasally, intravenously, intramuscularly, intraperitoneally, intracerebrospinal, intracranially, intrathecally, subcutaneously, intraarticularly, intrasynovially, or intraspinally.
[0024] Another aspect of the present disclosure relates to a method for treating congenital glycosylation disorders (CDGs) in a subject in need thereof by administering to the subject a composition of any of the preceding embodiments. In some embodiments, the congenital glycosylation disorder (CDG) is selected from CDG type I disorder, CDG-Ia disorder, CDG type II disorder, CDG-IIc disorder, and CDG-IIf disorder. In some embodiments, the congenital glycosylation disorder (CDG) is CDG-Ia disorder. In some embodiments, the composition is administered orally, topically, cutaneously, nasally, intravenously, intramuscularly, intraperitoneally, intracerebrospinal, intracranially, intrathecally, subcutaneously, intraarticularly, intrasynovially, or intraspinally.
[0025] Description of the drawings The present application can be best understood by reference to the following description taken in conjunction with the accompanying drawings contained herein. [Brief description of the drawings]
[0026] [Figure 1] FIG. 1 shows the in vitro M1P leakage profile under physiological conditions: n=3.
[0027] [Figure 2A] Figure 2A shows the aggregation profile of Lipo-M1P in phosphate buffered saline (PBS) at pH 7.4 with a size distribution in the nanometer range, and Figure 2B shows the concentration of micron-sized particles of Lipo-M1P in PBS at pH 7.4. [Figure 2B] Figure 2A shows the aggregation profile of Lipo-M1P in phosphate buffered saline (PBS) at pH 7.4 with a size distribution in the nanometer range, and Figure 2B shows the concentration of micron-sized particles of Lipo-M1P in PBS at pH 7.4.
[0028] [Figure 3A]Figures 3A and 3B show the biological activity of Lipo-M1P in PMM2-CDG fibroblasts. The Lipo-M1P dose response study is shown in Figure 3A. The cell viability of Lipo-M1P at the concentrations tested in the dose response study is shown in Figure 3B. [Figure 3B] Figures 3A and 3B show the biological activity of Lipo-M1P in PMM2-CDG fibroblasts. The Lipo-M1P dose response study is shown in Figure 3A. The cell viability of Lipo-M1P at the concentrations tested in the dose response study is shown in Figure 3B.
[0029] [Figure 4] FIG. 4 shows FACE gels of normal LLO and PMM2-CDG fibroblasts from two patients before and after treatment with Lipo-M1P.
[0030] [Diagram 5] FIG. 5 shows Western blots of normal ICAM-1 and PMM2-CDG fibroblasts untreated and treated with different concentrations of Lipo-M1P.
[0031] [Figure 6A] Figure 6A shows the distribution of Lipo-M1P to the liver, expressed as a percentage of the total dose, and Figure 6B shows the uptake of liposomes into hepatocytes and NPCs. [Figure 6B] Figure 6A shows the distribution of Lipo-M1P to the liver, expressed as a percentage of the total dose, and Figure 6B shows the uptake of liposomes into hepatocytes and NPCs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] Detailed Description The present disclosure is based on the inventors' discovery that certain liposome compositions are effective in encapsulating phosphorylated carbohydrates and delivering phosphorylated carbohydrates to the interior of cells. Provided herein are compositions of phosphorylated carbohydrates encapsulated by these liposomes that can deliver phosphorylated carbohydrates to the interior of cells, including, for example, the cytoplasm, endoplasmic reticulum, and Golgi. In some embodiments, the phosphorylated carbohydrate is mannose-1-phosphate or mannose-6-phosphate. Also provided herein are pharmaceutical compositions and kits containing these compositions. Also provided are methods for treating congenital glycosylation disorders (CDG) in a subject in need thereof by delivering phosphorylated carbohydrates to the interior of cells or administering such compositions to the subject.
[0033] The high negative charge and polarity generally makes it difficult for phosphorylated carbohydrates to cross liposomal membranes, which may limit how and when phosphorylated carbohydrates can be encapsulated within liposomes.
[0034] Unless otherwise defined, all scientific and technical terms are understood to have the same meaning as commonly used in the art to which they pertain. For purposes of this disclosure, the following terms are defined.
[0035] The term "about" as used herein refers to the normal error range for each value that is readily known to those skilled in the art. When referring to "about" a value or parameter herein, it includes (and describes) the embodiment that is directed to the value or parameter itself. For example, "about x" includes and describes "x" itself. In some embodiments, the term "about" refers to a variation of ±2% when used in connection with a measurement or when used to modify a value, unit, constant, or range of values.
[0036] When referring to "between" two values or parameters herein, it includes (describes) embodiments that include those two values or parameters themselves. For example, a description that refers to "between x and y" includes a description of "x" and "y" themselves. It should further be understood that "between x and y" can also be expressed as "about x to y" or "about x to y."
[0037] As used herein, mole percent also refers to "mol %."
[0038] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. composition
[0039] Provided herein is a composition comprising a liposome comprising one or more lipid particles and at least one phosphorylated carbohydrate, wherein the at least one phosphorylated carbohydrate is encapsulated in the liposome. Liposomes
[0040] In some embodiments, the liposome is a vesicle composed of a lamellar phase lipid bilayer. Any suitable liposome known in the art may be used. In some embodiments, the liposome has a lamellar nanostructure.
[0041] The liposomes of the present disclosure may be prepared by any suitable method known in the art and disclosed herein.Examples of suitable methods for preparing liposomes include, for example, disruption of biological membranes, such as by mechanical dispersion, including ultrasonication, thin film hydration, emulsification, French pressure cell, extrusion, and reconstitution of dried vesicles; solvent dispersion, including ethanol injection, ether injection, double emulsion, reverse phase, and evaporation; and detergent removal method.
[0042] In certain embodiments, the liposome is a stealth liposome that may be immune-tolerant. In some embodiments, the stealth liposome is a liposome that is capable of avoiding detection by the immune system of a subject. Thus, the stealth liposome may be immune-tolerant. For example, the subject may be a human.
[0043] When an active or therapeutic agent, such as the carbohydrates of the present disclosure, is encapsulated in a liposome, the liposome provides the active or therapeutic agent with complete encapsulation, partial encapsulation, or both. In some variations, at least a portion of the carbohydrate may be encapsulated by the liposome and localized within the liposome core and / or on the liposome's interior surface (e.g., membrane). Alternatively, in other variations, the entire carbohydrate may be encapsulated by the liposome and localized within the liposome core and / or on the liposome's interior surface (e.g., membrane).
[0044] The liposome of the present disclosure contains one or more lipids.In some embodiments, lipids include biological or synthetic substances that are soluble or partially soluble in organic solvents, or partition into hydrophobic environments when present in aqueous phase.In some variations, lipids can be divided into at least three classes: (1) simple lipids, including, for example, fats, oils, and waxes; (2) compound lipids, including, for example, phospholipids and glycolipids; and (3) derived lipids, including, for example, steroids.
[0045] In some variations, lipid may be neutral lipid or amphipathic lipid.In some embodiments, neutral lipid is lipid that exists in either uncharged or neutral zwitterionic form at selected pH.At physiological pH, such lipid may include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebroside, and diacylglycerol.In some embodiments, amphipathic lipid is lipid that contains both polar water-soluble group and non-polar water-insoluble group.
[0046] Suitable lipids include, for example, bilayer-forming lipids, non-bilayer-forming lipids, amphipathic lipids, naturally occurring lipids, phospholipids, glycerolipids, sphingolipids, phosphatidylglycerols, phosphatidic acids, lysolipids, fatty acids, sphingomyelins, glycosphingolipids, glucolipids, glycolipids, sulfatides, lipids with ether-linked and ester-linked fatty acids, polymerizable lipids, synthetic lipids, and semi-synthetic lipids. Synthetic or semi-synthetic lipids may be generated via deacylation or reacylation of natural lipids. Suitable characteristics of synthetic and semi-synthetic lipids include, for example, myristoyl, palmitoyl, and stearoyl fatty acids. In some embodiments, when the lipid contains one or more than one ester-linked fatty acid, the fatty acid is a myristoyl fatty acid. In certain embodiments, the lipid is 1,2-dimyristoyl-glycerol (DMG) or a salt thereof. In other embodiments, when the lipid contains one or more than one ester-linked fatty acid, the fatty acid is a stearoyl fatty acid. In certain embodiments, the lipid is 1,2-diastearoylglycerol (DSG) or a salt thereof. In some embodiments, the liposomes of the present disclosure may contain a mixture of two or more types of lipids. Such mixtures may be in any ratio suitable for encapsulating the carbohydrates of the present disclosure and delivering such carbohydrates to the interior of a cell. In some embodiments, the liposomes of the present disclosure may contain a lipid selected from phospholipids, glycerolipids, sphingolipids, and any combination thereof. Such lipids disclosed herein have a polar head group and a fatty acid tail that may be linked, for example, by an ester or ether bond.
[0047] In some embodiments, the liposome of the present disclosure may contain one or more lipids with polar head group.The lipid may contain any suitable polar head group known in the art.Suitable polar head groups include, for example, choline, ethanolamine, serine, glycerol, inositol, and any combination thereof.
[0048] In some embodiments, the liposomes of the present disclosure may contain one or more than one phospholipid. The liposomes of the present disclosure may contain any suitable phospholipid known in the art. Suitable phospholipids include, for example, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidylinositol (PI), and any combination thereof. In some embodiments, the liposomes of the present disclosure may contain phosphatidylcholine (PC). In some embodiments, the liposomes of the present disclosure may contain phosphatidylethanolamine (PE). In certain embodiments, the liposomes of the present disclosure may contain phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
[0049] In some embodiments, the phospholipid comprises two hydrophobic fatty acid tails. In some embodiments, each of the fatty acid tails comprises an aliphatic chain; in some embodiments, the two fatty acid tails are the same. In some embodiments, the two fatty acid tails are different. In some embodiments, the aliphatic chain is unsaturated. In some embodiments, the aliphatic chain is saturated. In some embodiments, the aliphatic chain is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl. In some embodiments, the alkyl is linear. In some embodiments, each of the fatty acid chains is unsubstituted C 4~28 In some embodiments, each of the fatty acid chains is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 4~28 In some embodiments, each of the fatty acid chains is an unsubstituted C alkyl. 4~28In some embodiments, each of the fatty acid chains is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In some embodiments, each of the fatty acid chains has one or more double bonds. In some embodiments, the double bonds have a cis configuration. In some embodiments, the double bonds have a trans configuration. In some embodiments, each of the fatty acid chains is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 4~28 In some embodiments, each of the fatty acid chains is an optionally substituted C alkenyl. 10~28 Alkyl, optionally substituted C 10~28 Alkenyl, and optionally substituted C 10~28 alkynyl. Suitable phospholipids include, for example, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE), or a salt thereof, or a combination of any of the foregoing.
[0050] It should be generally understood that DPPG is also commonly referred to in the art as 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol); DOPG is also commonly referred to in the art as 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol); and N-C12-DOPE is also commonly referred to in the art as (2R)-5-hydroxy-2-{[(9Z)-octadec-9-enoyl]oxy}-5,10-dioxo-4,6-dioxa-9-aza-5λ(5)-phosphahenicosan-1-yl(9Z)-octadec-9-enoate.
[0051] In one variation, the phospholipid is: [ka] [ka] [ka] or a salt thereof, or any combination of the foregoing.
[0052] In some embodiments, one or more phospholipids are present at a concentration of up to about 10 mol percent, about 15 mol percent, about 20 mol percent, about 25 mol percent, about 30 mol percent, about 35 mol percent, about 40 mol percent, about 45 mol percent, about 50 mol percent, about 55 mol percent, about 60 mol percent, about 65 mol percent, about 70 mol percent, about 75 mol percent, about 80 mol percent, about 85 mol percent, or about 90 mol percent. In some embodiments, one or more phospholipids are present at a concentration of at least 5 mol percent, at least 10 mol percent, at least 15 mol percent, at least 20 mol percent, at least 25 mol percent, at least 30 mol percent, at least 35 mol percent, at least 40 mol percent, at least 45 mol percent, at least 50 mol percent, at least 55 mol percent, at least 60 mol percent, at least 65 mol percent, at least 70 mol percent, or at least 75 mol percent.
[0053] In some embodiments, the liposome further comprises a molecule that can minimize the degradation of the lipid particle and / or enhance the retention of the lipid particle when administered to a subject, and / or makes the lipid particle immune-tolerant when administered to a subject.In some embodiments, the molecule is a stealth molecule, such as ethylene oxide, ethylene oxide oligomers, ethylene oxide polymers, polyethylene glycol (PEG), or any combination thereof; and / or a PEGylated neutral lipid.It should be understood that in some variations, the PEGylated neutral lipid may be charged under physiological conditions.
[0054] In some embodiments, the PEGylated lipid is a lipid having an ester-linked fatty acid. In certain embodiments, the PEGylated lipid has the formula (X): [ka] (In the formula, each R yand R are independently a carbon chain), or a salt thereof. y is independently an unsaturated carbon chain. y is independently a saturated carbon chain. y are independently C10-28 alkyl. In one embodiment, the lipid of the PEGylated lipid is 1,2-dimyristoyl-glycerol (DMG). In one embodiment, the PEGylated lipid is PEG(2k)-DMG, which is DMG-PEG 2000 In one embodiment, the PEGylated lipid is: [ka] or a salt thereof. In another embodiment, the lipid of the PEGylated lipid is 1,2-distearoylglycerol (DSG). In one embodiment, the PEGylated lipid is PEG(2k)-DSG, which is DSG-PEG 2000 In one embodiment, the PEGylated lipid is [ka] or a salt thereof.
[0055] In other embodiments, at least one phospholipid is conjugated to polyethylene glycol (PEG). In some embodiments, one phospholipid is conjugated to PEG. PEG can be conjugated to one or more of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidylinositol (PI), and any combination thereof. In certain embodiments, the lipid particles of the present disclosure can contain PEG conjugated to phosphatidylcholine (PC). In some embodiments, the phospholipid conjugated to the PEG is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or a salt thereof. In some embodiments, the phospholipid conjugated to the PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) or a salt thereof. In some embodiments, the PEGylated phospholipid is DSPE-PEG. In some embodiments, the PEGylated phospholipid is DSPE-PEG. 2000 In some embodiments, the DSPE-PEG is further conjugated to a carbohydrate. In certain embodiments, the DSPE-PEG is further conjugated to a monosaccharide. In some embodiments, the DSPE-PEG is further conjugated to a galactose moiety. In certain embodiments, the DSPE-PEG-galactose has the following structure: [ka] or a salt thereof.
[0056] In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure at a concentration ranging from about 0.5 mole percent to about 20 mole percent. In some embodiments, PEG may be present in the liposomes of the present disclosure at a concentration of about 0.5 mole percent, about 1 mole percent, about 2 mole percent, about 3 mole percent, about 4 mole percent, about 5 mole percent, about 6 mole percent, about 7 mole percent, about 8 mole percent, about 9 mole percent, about 10 mole percent, about 11 mole percent, about 12 mole percent, about 13 mole percent, about 14 mole percent, about 15 mole percent, about 16 mole percent, about 17 mole percent, about 18 mole percent, about 19 mole percent, or about 20 mole percent. In some embodiments, PEG may be present in the liposomes of the present disclosure at a concentration of at least about 0.5 mole percent, at least about 1 mole percent, at least about 2 mole percent, at least about 3 mole percent, at least about 4 mole percent, at least about 5 mole percent, at least about 6 mole percent, at least about 7 mole percent, at least about 8 mole percent, at least about 9 mole percent, at least about 10 mole percent, at least about 11 mole percent, at least about 12 mole percent, at least about 13 mole percent, at least about 14 mole percent, at least about 15 mole percent, at least about 16 mole percent, at least about 17 mole percent, at least about 18 mole percent, at least about 19 mole percent, or at least about 20 mole percent; or between 0.5 mole percent and 50 mole percent, between 0.5 mole percent and 40 mole percent, between 0.5 mole percent and 30 mole percent, or between 0.5 mole percent and 20 mole percent. In certain embodiments, phospholipids conjugated to polyethylene glycol (PEG) may be present in the liposomes of the present disclosure at a concentration of about 3 mole percent. In certain embodiments, phospholipids conjugated to polyethylene glycol (PEG) may be present in liposomes of the present disclosure at a concentration of about 5 mole percent.
[0057] In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure at a molecular weight ranging from about 200 Da to about 40,000 Da. In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure at a molecular weight ranging from about 200 Da to about 10,000 Da. In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure at a molecular weight ranging from about 200 Da to about 300 Da, about 400 Da, about 500 Da, about 600 Da, about 700 Da, about 800 Da, about 900 Da, about 1,000 Da, about 1,500 Da, about 2,000 Da, about 2,500 Da, about 3,000 Da, about 3,500 Da, about 4, 000 Da, about 4,500 Da, about 5,000 Da, about 5,500 Da, about 6,000 Da, about 6,500 Da, about 7,000 Da, about 7,500 Da, about 8,000 Da, about 8,500 Da, about 9,000 Da, about 9,500 Da, or about 10,000 Da; or between about 200 Da and about 10,000 Da.
[0058] In some embodiments, the liposome further comprises one or more sterols. In some embodiments, the one or more sterols comprise one or more neutral sterols. In other embodiments, the one or more sterols comprise one or more charged sterols. In yet other embodiments, the one or more sterols comprise a combination of neutral and charged sterols. Suitable phospholipids include, for example, cholesterol and cholesteryl hemisuccinate (CHEMS), dicetyl phosphate, and Solulan C24. In some embodiments, the one or more charged sterols comprise CHEMS. In other embodiments, the liposome further comprises cholesterol, also referred to herein as "Chol". In one variation, the liposome further comprises: [ka] or a salt thereof.
[0059] In some embodiments, the sterols of the present disclosure, such as cholesterol or CHEMS, may be present in the liposomes of the present disclosure at a concentration of up to about 5 mol percent, about 10 mol percent, about 15 mol percent, about 20 mol percent, about 30 mol percent, about 40 mol percent, or about 50 mol percent; or at least 5 mol percent, at least 10 mol percent, at least 15 mol percent, at least 20 mol percent, at least 25 mol percent, at least 30 mol percent, at least 35 mol percent, or at least 40 mol percent; or between 5 mol percent and 50 mol percent. In certain embodiments, the sterols of the present disclosure, such as cholesterol or CHEMS, may be present in the liposomes of the present disclosure at a concentration of up to 15 mol percent. In certain embodiments, the sterols of the present disclosure, such as cholesterol or CHEMS, may be present in the liposomes of the present disclosure at a concentration of about 3 mol percent, about 5 mol percent, about 20 mol percent, or about 30 mol percent. In some embodiments, sterols of the present disclosure, such as cholesterol or CHEMS, may be present in liposomes of the present disclosure in a 1:1 or 2:1 molar ratio.
[0060] In some embodiments, the liposomes of the present disclosure have an average particle size ranging from about 0.02 microns in diameter to about 0.5 microns in diameter. In certain embodiments, the liposomes of the present disclosure have an average particle size of about 0.02 microns in diameter, about 0.03 microns in diameter, about 0.04 microns in diameter, about 0.05 microns in diameter, about 0.06 microns in diameter, about 0.07 microns in diameter, about 0.08 microns in diameter, about 0.09 microns in diameter, about 0.1 microns in diameter, about 0.15 microns in diameter, about 0.2 microns in diameter, about 0.25 microns in diameter, about 0.3 microns in diameter, about 0.35 microns in diameter, about 0.4 microns in diameter, about 0.45 microns in diameter, or about 0.5 microns in diameter. In some embodiments, the liposomes of the present disclosure have an average particle size of about 0.025 microns to about 0.25 microns. In some embodiments, liposomes of the present disclosure have an average particle size of about 0.025 microns to about 0.05 microns, about 0.05 microns to about 0.1 microns, about 0.1 microns to about 0.2 microns, about 0.2 microns to about 0.3 microns, about 0.3 microns to about 0.4 microns, about 0.4 microns to about 0.5 microns, or about 0.04 microns to about 0.22 microns.
[0061] In one embodiment, the liposome comprises: i) at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail being at least one C 10~28 at least one phospholipid containing a carbon chain; ii) (a) to (c): a) at least one phospholipid having a polar head group and a saturated fatty acid tail; b) at least one phospholipid having a polar head group and an unsaturated fatty acid tail, the polar head group comprising a quaternary ammonium cation, a glycerol group, or a serine group; and c) at least one acidic cholesterol ester or cholesterol one or more of; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. Includes.
[0062] In some embodiments, the unsaturated fatty acid tail of the liposome in i) is optionally substituted C 10~28 Alkenyl and optionally substituted C 10~28 In some embodiments, each of the fatty acid chains is selected from the group consisting of unsubstituted C 10~28 In some embodiments, each of the fatty acid chains is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In some embodiments, each of the fatty acid chains has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, each of the fatty acid chains is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 10~28 alkenyl. In some embodiments, the at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail in i) of the liposome is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a salt thereof. In one variation, the at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail in i) of the liposome is: [ka] or a salt thereof.
[0063] In some embodiments, the at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail in i) is present in an amount of up to about 15 mole percent, about 20 mole percent, about 25 mole percent, about 30 mole percent, about 35 mole percent, about 40 mole percent, about 45 mole percent, about 50 mole percent, about 55 mole percent, about 60 mole percent, about 65 mole percent, about 70 mole percent, about 75 mole percent, about 80 mole percent, about 85 mole percent, or about 90 mole percent. In some embodiments, the at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail in i) is present in an amount of at least about 10 mole percent, at least about 20 mole percent, at least about 30 mole percent, at least about 40 mole percent, at least about 50 mole percent, at least about 60 mole percent, at least about 70 mole percent, or at least about 80 mole percent; or between about 10 mole percent and 80 mole percent. In some embodiments, the at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail in i) is present in an amount of about 10-20 molar percent, about 20-30 molar percent, about 30-40 molar percent, about 40-50 molar percent, about 50-60 molar percent, about 60-70 molar percent, about 70-80 molar percent, about 10-30 molar percent, about 30-50 molar percent, about 50-80 molar percent, about 10-50 molar percent, or about 40-80 molar percent.
[0064] In some embodiments, the polar head group in ii)a) of the liposome is selected from the group consisting of glycerol, choline, phosphate, and serine. In some embodiments, the polar head group in ii)a) of the liposome is choline. In some embodiments, the saturated fatty acid tail is an optionally substituted alkyl. In some embodiments, the saturated fatty acid tail is an unsubstituted C 4~28In some embodiments, the saturated fatty acid tail is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 4~28 In some embodiments, the at least one phospholipid having a polar head group and a saturated fatty acid tail in ii)a) of the liposome is 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), or a salt thereof. In one variation, the at least one phospholipid having a polar head group and a saturated fatty acid tail in ii)a) of the liposome is: [ka] or a salt thereof.
[0065] In some embodiments, the unsaturated fatty acid tail in ii)b) of the liposome is selected from the group consisting of optionally substituted alkenyl and optionally substituted alkynyl. In some embodiments, the unsaturated fatty acid tail in ii)b) of the liposome is selected from the group consisting of unsubstituted C 10~28 In some embodiments, the unsaturated fatty acid tail in ii)b) of the liposome has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, the unsaturated fatty acid tail in ii)b) of the liposome has an unsubstituted C 10~28In some embodiments, the unsaturated fatty acid tail in ii)b) of the liposome is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 10~28 Alkenyl. Suitable phospholipids include, for example, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or a salt thereof. In one variation, the phospholipid is: [ka] or a salt thereof.
[0066] In some embodiments, the at least one acidic cholesterol ester in ii)c) of the liposome is cholesteryl hemisuccinate (CHEMS). In one variation, the at least one acidic cholesterol ester in ii)c) of the liposome is: [ka] or a salt thereof.
[0067] In some embodiments, one or more of a)-c) in ii) of the liposome is present in an amount of up to about 5 molar percent, about 10 molar percent, about 15 molar percent, about 20 molar percent, about 25 molar percent, about 30 molar percent, about 35 molar percent, about 40 molar percent, about 45 molar percent, about 50 molar percent, about 55 molar percent, about 60 molar percent, about 65 molar percent, or about 70 molar percent. In some embodiments, one or more of a)-c) in ii) of the liposome is present in an amount of at least about 5 molar percent, at least about 10 molar percent, at least about 15 molar percent, at least about 20 molar percent, at least about 25 molar percent, at least about 30 molar percent, at least about 35 molar percent, at least about 40 molar percent, at least about 45 molar percent, at least about 50 molar percent, at least about 55 molar percent, or at least about 60 molar percent. In some embodiments, one or more of a)-c) in ii) of the liposome is present in an amount of about 5-10 molar percent, about 10-15 molar percent, about 15-20 molar percent, about 20-25 molar percent, about 25-30 molar percent, about 30-35 molar percent, about 35-40 molar percent, about 40-45 molar percent, about 45-50 molar percent, about 50-55 molar percent, about 55-60 molar percent, about 60-65 molar percent, about 65-70 molar percent, about 5-25 molar percent, about 25-50 molar percent, or about 50-70 molar percent.
[0068] In some embodiments, the at least one phospholipid conjugated to PEG is phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), or phosphatidylinositol (PI). In some embodiments, such phospholipids are 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or salts thereof. In some embodiments, such phospholipids are 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) or salts thereof.
[0069] In one variation, the phospholipid conjugated to PEG is: [ka] [ka] or a salt thereof.
[0070] In some embodiments, the conjugated PEG is present in the liposome at a concentration ranging from about 0.5 mole percent to about 20 mole percent. In some embodiments, the conjugated PEG is present in the liposome at a concentration of about 0.5 mole percent, about 1 mole percent, about 2 mole percent, about 3 mole percent, about 4 mole percent, about 5 mole percent, about 6 mole percent, about 7 mole percent, about 8 mole percent, about 9 mole percent, about 10 mole percent, about 11 mole percent, about 12 mole percent, about 13 mole percent, about 14 mole percent, about 15 mole percent, about 16 mole percent, about 17 mole percent, about 18 mole percent, about 19 mole percent, or about 20 mole percent; or between about 0.5 mole percent and 20 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 3 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 5 mole percent.
[0071] In some embodiments, DOPE is present in the liposome composition in an amount of about 0-80 mole percent, about 10-80 mole percent, about 20-80 mole percent, or about 30-80 mole percent, about 10-70 mole percent, about 20-70 mole percent, about 30-70 mole percent, about 30-60 mole percent, about 40-60 mole percent, about 30-35 mole percent, about 35-40 mole percent, about 40-45 mole percent, about 45-50 mole percent, about 50-55 mole percent, about 55-60 mole percent, about 60-65 mole percent, about 65-70 mole percent, or about 70-75 mole percent. In some variations, DOPE is present in an amount of about 0-30 mole percent, about 5-30 mole percent, about 10-30 mole percent, about 15-30 mole percent, about 20-30 mole percent, or about 25-30 mole percent. In other variations, DOPE is present in an amount of about 0-5 mole percent, about 0-10 mole percent, about 0-15 mole percent, about 0-20 mole percent, or about 0-25 mole percent.
[0072] In some embodiments, the liposome composition comprises N-C12-DOPE. In some embodiments, N-C12-DOPE is present in an amount of about 0-80 molar percent, about 60-80 molar percent, about 65-80 molar percent, about 70-80 molar percent, or about 75-80 molar percent. In other embodiments, N-C12-DOPE is present in an amount of about 60-65 molar percent, about 65-70 molar percent, about 70-75 molar percent, or about 75-80 molar percent.
[0073] In some embodiments, DOPC is present in an amount of about 0-75 mole percent, about 10-75 mole percent, about 35-75 mole percent, about 35-70 mole percent, about 35-65 mole percent, about 35-60 mole percent, about 35-55 mole percent, or about 35-50 mole percent. In other embodiments, DOPC is present in an amount of about 10-15 mole percent, about 15-20 mole percent, about 20-25 mole percent, about 25-30 mole percent, about 30-35 mole percent, about 35-40 mole percent, about 40-45 mole percent, about 45-50 mole percent, about 50-55 mole percent, about 55-60 mole percent, or about 60-65 mole percent.
[0074] In some embodiments, DSPE-PEG is present in an amount of about 0-20 mole percent, about 0-10 mole percent, about 0-9 mole percent, about 0-8 mole percent, about 0-7 mole percent, about 0-6 mole percent, about 0-5 mole percent, or about 0-4 mole percent, while in other embodiments, DSPE-PEG is present in an amount of about 0.1-10 mole percent, about 0.1-6 mole percent, or about 0.1-4 mole percent.
[0075] In some embodiments, the liposome composition further comprises a sterol. In some embodiments, the sterol is cholesterol. In other embodiments, the sterol is CHEMS. In certain embodiments, the sterol is present in an amount of about 0-50 mole percent, about 0-45 mole percent, about 0-40 mole percent, about 30-40 mole percent, about 0-25 mole percent, about 0-20 mole percent, about 0-15 mole percent, about 0-10 mole percent, about 0-7 mole percent, about 0-6 mole percent, or about 0-5 mole percent. In other embodiments, the sterol is present in an amount of about 5-10 mole percent, about 10-15 mole percent, about 15-20 mole percent, about 20-25 mole percent, or about 25-30 mole percent. In yet other embodiments, the sterol is present in an amount of about 5-20 mole percent.
[0076] In some embodiments, the liposome composition comprises DOPE, DOPC, and DSPE-PEG. In certain embodiments, the DSPE-PEG is 350-2000 , DSPE-PEG 350-5000 , DSPE-PEG 350-10000 , or DSPE-PEG 350-40000 or DSPE-PEG 1000 , DSPE-PEG 2000 , DSPE-PEG 5000 , or DSPE-PEG 10000 In other embodiments, the liposome composition further comprises N-C12-DOPE. In yet other embodiments, the liposome composition further comprises cholesterol. In yet other embodiments, the liposome composition further comprises CHEMS.
[0077] In some embodiments, the liposome composition comprises N-C12-DOPE, DOPC, and DSPE-PEG. In certain embodiments, DSPE-PEG is 350-2000 , DSPE-PEG 350-5000 , DSPE-PEG 350-10000 , or DSPE-PEG 350-40000 or DSPE-PEG1000 , DSPE-PEG 2000 , DSPE-PEG 5000 , or DSPE-PEG 10000 In another embodiment, the liposome composition further comprises DOPE. In yet another embodiment, the liposome composition further comprises cholesterol.
[0078] It is understood that each of the components listed in any of the liposomal compositions described herein may be present in any combination of the amounts described.
[0079] In one embodiment, the liposome comprises: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a salt thereof; ii) (a) a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine; and C 10~28 one or more phospholipids having a fatty acid tail that includes an aliphatic chain; or (b) an acidic cholesterol ester, or a mixture of (a) and (b); one or more stabilizers selected from: iii) PEG conjugated to at least one phospholipid. Includes.
[0080] In one variation, the liposome comprises: i) [ka] or salts thereof; ii) (a) a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine; and C 10~28 and one or more phospholipids having a fatty acid tail that includes an aliphatic chain; or (b) an acidic cholesterol ester, or a mixture of (a) and (b); one or more stabilizers selected from: iii) PEG conjugated to at least one phospholipid. Includes.
[0081] In some embodiments, DOPE in i) is present in an amount of up to about 15 mol percent, about 20 mol percent, about 25 mol percent, about 30 mol percent, about 35 mol percent, about 40 mol percent, about 45 mol percent, about 50 mol percent, about 55 mol percent, about 60 mol percent, about 65 mol percent, about 70 mol percent, about 75 mol percent, about 80 mol percent, about 85 mol percent, or about 90 mol percent. In some embodiments, DOPE in i) is present in an amount of at least about 10 mol percent, at least about 20 mol percent, at least about 30 mol percent, at least about 40 mol percent, at least about 50 mol percent, at least about 60 mol percent, at least about 70 mol percent, or at least about 80 mol percent. In some embodiments, DOPE in i) is present in an amount of about 10-20 mole percent, about 20-30 mole percent, about 30-40 mole percent, about 40-50 mole percent, about 50-60 mole percent, about 60-70 mole percent, about 70-80 mole percent, about 10-30 mole percent, about 30-50 mole percent, about 50-80 mole percent, about 10-50 mole percent, or about 40-80 mole percent.
[0082] In some embodiments, the C in ii)a) of the liposome 10~28 The aliphatic chain is unsaturated. In some embodiments, the C in ii)a) of the liposome 10~28 The aliphatic chain is saturated. In some embodiments, the C in ii)a) of the liposome 10~28 The aliphatic chain may be optionally substituted C 10~28 Alkyl, optionally substituted C 10~28 Alkenyl, and optionally substituted C 10~28 In some embodiments, C is selected from the group consisting of alkynyl. 10~28 The alkyl is linear or branched. In some embodiments, the C in ii)a) of the liposome10~28 The aliphatic chain is an unsubstituted C 10~28 In some embodiments, the C in ii)a) of the liposome is alkyl. 10~28 The aliphatic chain is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 10~28 In some embodiments, the C in ii)a) of the liposome is alkyl. 10~28 The aliphatic chain is an unsubstituted C 10~28 In some embodiments, the alkenyl is linear or branched. In some embodiments, the C in ii)a) of the liposome is 10~28 The aliphatic chain has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, the C in ii)a) of the liposome 10~28 The aliphatic chain is a C substituted with a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. 10~28 Suitable phospholipids include, for example, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or combinations thereof.
[0083] In some embodiments, C 10~28 Aliphatic chain is C 10~26 In another embodiment, C 10~28 The aliphatic chain is C 10~24 In yet another embodiment, C 10~28 Aliphatic chain is C10~22 In another embodiment, C 10~28 The aliphatic chain is C 10~20 In yet another embodiment, C 10~28 The aliphatic chain is C 10~18 In some embodiments, C 10~28 Aliphatic chain is C 10~16 In another embodiment, C 10~28 Aliphatic chain is C 10~14 In yet another embodiment, C 10~28 Aliphatic chain is C 10~12 In some embodiments, C 10~28 Aliphatic chain is C 14~18 It is an aliphatic chain.
[0084] In some embodiments, the acidic cholesterol ester in ii)b) of the liposome is cholesteryl hemisuccinate (CHEMS). In one variation, the acidic cholesterol ester in ii)b) of the liposome is: [ka] or a salt thereof.
[0085] In some embodiments, the one or more stabilizers in ii) of the liposome are present in an amount of up to about 5 mole percent, about 10 mole percent, about 15 mole percent, about 20 mole percent, about 25 mole percent, about 30 mole percent, about 35 mole percent, about 40 mole percent, about 45 mole percent, about 50 mole percent, about 55 mole percent, about 60 mole percent, about 65 mole percent, or about 70 mole percent. In some embodiments, the one or more stabilizers in ii) of the liposome are present in an amount of at least about 5 mole percent, at least about 10 mole percent, at least about 15 mole percent, at least about 20 mole percent, at least about 25 mole percent, at least about 30 mole percent, at least about 35 mole percent, at least about 40 mole percent, at least about 45 mole percent, at least about 50 mole percent, at least about 55 mole percent, or at least about 60 mole percent. In some embodiments, the one or more stabilizers in ii) of the liposome are present in an amount of about 5-10 molar percent, about 10-15 molar percent, about 15-20 molar percent, about 20-25 molar percent, about 25-30 molar percent, about 30-35 molar percent, about 35-40 molar percent, about 40-45 molar percent, about 45-50 molar percent, about 50-55 molar percent, about 55-60 molar percent, about 60-65 molar percent, about 65-70 molar percent, about 5-25 molar percent, about 25-50 molar percent, or about 50-70 molar percent.
[0086] In some embodiments, the at least one phospholipid conjugated to PEG is selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), and phosphatidylinositol (PI). In some embodiments, such phospholipids are 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or a salt thereof. In some embodiments, such phospholipids are 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or a salt thereof.
[0087] In one variation, the phospholipid conjugated to PEG is: [ka] [ka] or a salt thereof.
[0088] In some embodiments, the conjugated PEG is present in the liposome at a concentration ranging from about 0.5 mole percent to about 20 mole percent. In some embodiments, the conjugated PEG is present in the liposome at a concentration of about 0.5 mole percent, about 1 mole percent, about 2 mole percent, about 3 mole percent, about 4 mole percent, about 5 mole percent, about 6 mole percent, about 7 mole percent, about 8 mole percent, about 9 mole percent, about 10 mole percent, about 11 mole percent, about 12 mole percent, about 13 mole percent, about 14 mole percent, about 15 mole percent, about 16 mole percent, about 17 mole percent, about 18 mole percent, about 19 mole percent, or about 20 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 3 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 5 mole percent.
[0089] In some embodiments, the liposome further comprises cholesterol, hi some embodiments, the cholesterol is present in an amount up to about 10 mole percent, about 15 mole percent, about 20 mole percent, about 25 mole percent, about 30 mole percent, about 35 mole percent, or about 40 mole percent.
[0090] In another embodiment, the liposome comprises: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b at least one of the carbon chains is unsaturated; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b each of which is an unsaturated carbon chain; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2 substituted alkyl) or a salt thereof; [ka] (In the formula: T 3a and T 3b each of which is a saturated carbon chain; G 3 is H, or alkyl substituted with at least one -OH), or a salt thereof; and [ka] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. Includes.
[0091] In yet another embodiment, the liposome comprises: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b at least one of the carbon chains is unsaturated; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b each of which is an unsaturated carbon chain; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2 substituted alkyl) or a salt thereof; [ka] (In the formula: T 3a and T 3b each of which is a carbon chain; G 3 is H, or alkyl substituted with at least one -OH), or a salt thereof; and [ka] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. Includes.
[0092] "Aminoalkyl" refers to an alkyl chain substituted with an amino group. Thus, in formula (PL-1), the alkyl chain is connected to the oxygen atom of the phosphate moiety. In some embodiments, R 1 Amino-substituted C 1~6 In some embodiments, the amino substituted C 1~6 In some embodiments, R in formula (PL-1) is linear or branched. 1 C 1~6 Alkyl-NH 2 In some embodiments, R in formula (PL-1) is 1 is aminoethyl, -CH 2 CH 2 NH 2In some embodiments, T 1a and T 1b Each of these is independent of C 10~28 Alkenyl or C 10~28 In some embodiments, C is alkynyl. 10~28 In some embodiments, the alkenyl is linear or branched. 10~28 An alkenyl has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, C 10~28 The alkenyl is substituted by a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In some embodiments, the phospholipid of formula (PL-1) is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a salt thereof. In one variation, the phospholipid of formula (PL-1) is [ka] or a salt thereof.
[0093] In some embodiments, the phospholipid of formula (PL-1) is present in an amount of up to about 15 mol percent, about 20 mol percent, about 25 mol percent, about 30 mol percent, about 35 mol percent, about 40 mol percent, about 45 mol percent, about 50 mol percent, about 55 mol percent, about 60 mol percent, about 65 mol percent, about 70 mol percent, about 75 mol percent, about 80 mol percent, about 85 mol percent, or about 90 mol percent. In some embodiments, the phospholipid of formula (PL-1) is present in an amount of at least about 10 mol percent, at least about 20 mol percent, at least about 30 mol percent, at least about 40 mol percent, at least about 50 mol percent, at least about 60 mol percent, at least about 70 mol percent, or at least about 80 mol percent. In some embodiments, the phospholipid of formula (PL-1) is present in an amount of about 10-20 molar percent, about 20-30 molar percent, about 30-40 molar percent, about 40-50 molar percent, about 50-60 molar percent, about 60-70 molar percent, about 70-80 molar percent, about 10-30 molar percent, about 30-50 molar percent, about 50-80 molar percent, about 10-50 molar percent, or about 40-80 molar percent.
[0094] In some embodiments, R of formula (PL-2) 2 is an alkyl or glycerol substituted with a quaternary ammonium. 2 is a quaternary ammonium substituted C 1~6 In some embodiments, the quaternary ammonium is [ka] In other embodiments, the quaternary ammonium is one or more C 1~6 In one embodiment, the quaternary ammonium is [ka] In some embodiments, R in formula (PL-2) is 2 is choline. In some embodiments, R 2 -COOH and -NH 2 In some embodiments, R of formula (PL-2) is an alkyl substituted with 2 -COOH and NH 2 C replaced with 1~6 In some embodiments, R in formula (PL-2) is alkyl. 2 In some embodiments, R in formula (PL-2) is serine. 2 is L-serine. 2a and T 2b Each of these is independent of C 10~28 Alkenyl or C 10~28 In some embodiments, C is alkynyl. 10~28 In some embodiments, the alkenyl is linear or branched. 10~28 An alkenyl has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, C 10~28 In some embodiments, the alkenyl is unsubstituted. 10~28 The alkenyl is substituted by a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In some embodiments, the phospholipid of formula (PL-2) is 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or a salt thereof.
[0095] In some embodiments, G of formula (PL-3) or formula (PL-3A) 3 is H. In some embodiments, G of formula (PL-3) or formula (PL-3A) 3In some embodiments, G of Formula (PL-3) or Formula (PL-3A) is alkyl substituted with at least one -OH. 3 In some embodiments, G of Formula (PL-3) or Formula (PL-3A) is an alkyl substituted with two -OH. 3 is glycerol. In some embodiments of Formula (PL-3) or Formula (PL-3A), T 3a and T 3b is independently a saturated carbon chain. In some embodiments, the saturated carbon chain is optionally substituted 10~28 In some embodiments, C 10~28 The alkyl is linear or branched. In some embodiments, 10~28 In some embodiments, the alkyl is unsubstituted. 3a and T 3b each of which is independently substituted by a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl; 10~28 In some embodiments, the phospholipid of formula (PL-3) or formula (PL-3A) is 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG) or 1,2-distearoyl-sn-glycero-3-phosphate (DSPA). In some embodiments of formula (PL-3A), the T in formula (PL-3A) is 3a and T 3b Each of is independently an unsaturated carbon chain. In some embodiments of Formula (PL-3A), T 3a and T 3b Each of these is independent of C 10~28 Alkenyl or C 10~28 In some embodiments, C is alkynyl. 10~28 In some embodiments, the alkenyl is linear or branched. 10~28An alkenyl has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, C 10~28 In some embodiments, the alkenyl is unsubstituted. 10~28 The alkenyl is substituted by a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In another embodiment, the phospholipid of formula (PL-3A) is 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) or a salt thereof.
[0096] In some embodiments, Z of formula (CE) 1 is C substituted with -COOH 1~6 In some embodiments, Formula (CE) is cholesteryl hemisuccinate or a salt thereof.
[0097] In some embodiments, at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), at least one phospholipid of formula (PL-3A), or at least one cholesterol ester of formula (CE), or any combination of the foregoing, is present in an amount of up to about 5 molar percent, about 10 molar percent, about 15 molar percent, about 20 molar percent, about 25 molar percent, about 30 molar percent, about 35 molar percent, about 40 molar percent, about 45 molar percent, about 50 molar percent, about 55 molar percent, about 60 molar percent, about 65 molar percent, or about 70 molar percent. In some embodiments, at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), at least one phospholipid of formula (PL-3A), or at least one cholesterol ester of formula (CE), or any combination of the foregoing, is present in an amount of at least about 5 molar percent, at least about 10 molar percent, at least about 15 molar percent, at least about 20 molar percent, at least about 25 molar percent, at least about 30 molar percent, at least about 35 molar percent, at least about 40 molar percent, at least about 45 molar percent, at least about 50 molar percent, at least about 55 molar percent, or at least about 60 molar percent. In some embodiments, at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), at least one phospholipid of formula (PL-3A), or at least one cholesterol ester of formula (CE), or any combination of the foregoing, is present in an amount of about 5-10 molar percent, about 10-15 molar percent, about 15-20 molar percent, about 20-25 molar percent, about 25-30 molar percent, about 30-35 molar percent, about 35-40 molar percent, about 40-45 molar percent, about 45-50 molar percent, about 50-55 molar percent, about 55-60 molar percent, about 60-65 molar percent, about 65-70 molar percent, about 5-25 molar percent, about 25-50 molar percent, or about 50-70 molar percent.
[0098] In some embodiments, the at least one phospholipid conjugated to PEG is selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), and phosphatidylinositol (PI). In some embodiments, such phospholipids are 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or salts thereof. In some embodiments, such phospholipids conjugated to PEG are 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or salts thereof.
[0099] In one variation, the phospholipid conjugated to PEG is: [ka] [ka] or a salt thereof.
[0100] In some embodiments, the conjugated PEG is present in the liposome at a concentration ranging from about 0.5 mole percent to about 20 mole percent. In some embodiments, the conjugated PEG is present in the liposome at a concentration of about 0.5 mole percent, about 1 mole percent, about 2 mole percent, about 3 mole percent, about 4 mole percent, about 5 mole percent, about 6 mole percent, about 7 mole percent, about 8 mole percent, about 9 mole percent, about 10 mole percent, about 11 mole percent, about 12 mole percent, about 13 mole percent, about 14 mole percent, about 15 mole percent, about 16 mole percent, about 17 mole percent, about 18 mole percent, about 19 mole percent, or about 20 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 3 mole percent. In certain embodiments, the conjugated PEG is present in the liposome at a concentration of about 5 mole percent.
[0101] In some embodiments, the liposome further comprises cholesterol, hi some embodiments, the cholesterol is present in an amount up to about 10 mole percent, about 15 mole percent, about 20 mole percent, about 25 mole percent, about 30 mole percent, about 35 mole percent, or about 40 mole percent.
[0102] In another embodiment, the liposome comprises: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE) or a salt thereof; and ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or a salt thereof Includes.
[0103] In another embodiment, the liposome comprises: i) [ka] or a salt thereof; and ii) [ka] or its salt Includes.
[0104] In some embodiments, N-C12-DOPE is present in an amount of up to about 40 mol percent, about 45 mol percent, about 50 mol percent, about 55 mol percent, about 60 mol percent, about 65 mol percent, about 70 mol percent, about 75 mol percent, about 80 mol percent, about 85 mol percent, or about 90 mol percent. In some embodiments, N-C12-DOPE is present in an amount of at least about 30 mol percent, at least about 40 mol percent, at least about 50 mol percent, at least about 60 mol percent, at least about 70 mol percent, or at least about 80 mol percent. In some embodiments, N-C12-DOPE is present in an amount of about 30-40 mol percent, about 40-50 mol percent, about 50-60 mol percent, about 60-70 mol percent, about 70-80 mol percent, about 30-50 mol percent, or about 50-80 mol percent, or about 40-80 mol percent.
[0105] In some embodiments, DOPC is present in an amount of up to about 5 mole percent, about 10 mole percent, about 15 mole percent, about 20 mole percent, about 25 mole percent, about 30 mole percent, about 35 mole percent, about 40 mole percent, about 45 mole percent, about 50 mole percent, about 55 mole percent, or about 60 mole percent. In some embodiments, DOPC is present in an amount of at least about 5 mole percent, at least about 10 mole percent, at least about 15 mole percent, at least about 20 mole percent, at least about 25 mole percent, at least about 30 mole percent, at least about 35 mole percent, at least about 40 mole percent, at least about 45 mole percent, or at least about 50 mole percent. In some embodiments, DOPC is present in an amount of about 5-10 mole percent, about 10-15 mole percent, about 15-20 mole percent, about 20-25 mole percent, about 25-30 mole percent, about 30-35 mole percent, about 35-40 mole percent, about 40-45 mole percent, about 45-50 mole percent, about 50-55 mole percent, about 55-60 mole percent, about 5-30 mole percent, or about 30-50 mole percent.
[0106] In some embodiments, the liposome further comprises PEG conjugated to at least one phospholipid, cholesterol, CHEMS, or a combination of the foregoing. In some embodiments, the at least one phospholipid conjugated to PEG is phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), or phosphatidylinositol (PI). In some embodiments, such phospholipids are 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), 1,2-distearoyl-sn-glycero-3-phosphate (DSPA), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or a salt thereof. In some embodiments, at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), or a salt thereof.
[0107] In some embodiments, at least one phospholipid, cholesterol, CHEMS, or combination of the above is present in the liposome at a concentration ranging from about 0.5 mol percent to about 20 mol percent. In some embodiments, at least one phospholipid, cholesterol, CHEMS, or combination of the above is present in the liposome at a concentration of about 0.5 mol percent, about 1 mol percent, about 2 mol percent, about 3 mol percent, about 4 mol percent, about 5 mol percent, about 6 mol percent, about 7 mol percent, about 8 mol percent, about 9 mol percent, about 10 mol percent, about 11 mol percent, about 12 mol percent, about 13 mol percent, about 14 mol percent, about 15 mol percent, about 16 mol percent, about 17 mol percent, about 18 mol percent, about 19 mol percent, or about 20 mol percent. In certain embodiments, at least one phospholipid, cholesterol, CHEMS, or combination of the above is present in the liposome at a concentration of about 3 mol percent. In certain embodiments, at least one phospholipid, cholesterol, CHEMS, or a combination of the foregoing is present in the liposome at a concentration of about 5 mole percent.
[0108] In another embodiment, the liposome has formula (PL-4): [ka] (In the formula: T 1a and T 1b at least one of R is an unsaturated carbon chain; 4 is an aliphatic chain containing an amide moiety), or a salt thereof.
[0109] In some embodiments, R of formula (PL-4) 4 is an alkyl containing an amide moiety. 4 is a C containing an amide moiety 10~28 In some embodiments, R in formula (PL-4) is alkyl. 4 -C 1~12 Alkyl-NH-C(O)-C 1~12In certain embodiments, R in formula (PL-4) is alkyl. 4 -CH 2 CH 2 -NH-C(O)-C 11 H 23 In some embodiments, T 4a and T 4b Each of the following is independently 10~28 Alkenyl or C 10~28 In some embodiments, C is alkynyl. 10~28 The alkenyl is linear or branched. 10~28 An alkenyl has one or more double bonds. In some embodiments, each double bond has a cis configuration. In some embodiments, each double bond has a trans configuration. In some embodiments, C 10~28 The alkenyl is substituted by a substituent selected from the group consisting of acyl, hydroxyl, cycloalkyl, alkoxy, acyloxy, amino, aminoacyl, nitro, halo, thiol, thioalkyl, alkyl, alkenyl, alkynyl, and heterocyclyl. In some embodiments, the phospholipid of formula (PL-4) is N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE) or a salt thereof. In one variation, the phospholipid of formula (PL-4) is: [ka] or a salt thereof.
[0110] In some embodiments, the phospholipid of formula (PL-4) is present in an amount of up to about 40 mol percent, about 45 mol percent, about 50 mol percent, about 55 mol percent, about 60 mol percent, about 65 mol percent, about 70 mol percent, about 75 mol percent, about 80 mol percent, about 85 mol percent, or about 90 mol percent. In some embodiments, the phospholipid of formula (PL-4) is present in an amount of at least about 30 mol percent, at least about 40 mol percent, at least about 50 mol percent, at least about 60 mol percent, at least about 70 mol percent, or at least about 80 mol percent. In some embodiments, the phospholipid of formula (PL-4) is present in an amount of about 30-40 mol percent, about 40-50 mol percent, about 50-60 mol percent, about 60-70 mol percent, about 70-80 mol percent, about 30-50 mol percent, or about 50-80 mol percent, or about 40-80 mol percent.
[0111] In some embodiments, the liposome further comprises PEG conjugated to 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), at least one phospholipid, cholesterol, CHEMS, or a combination of the foregoing.
[0112] In some embodiments, the compound of formula (A): [ka] (In the formula, R X -SO 2 and -SO 2 The S atom of each R is replaced with an optionally substituted rhodamine. a and R are independently a carbon chain), or a salt thereof. a is independently an unsaturated carbon chain. a is independently a saturated carbon chain. b is C 10~28In one variation, the liposome comprises RH-DHPE. In one variation, the liposome comprises N-(lissamine rhodamine B sulfonyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, or a salt thereof. In one variation, the liposome comprises 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl), or a salt thereof. In one variation, the liposome comprises: [ka] or a salt thereof.
[0113] In some embodiments of the above aspect, the liposomes comprising at least one phospholipid of formula (A) may be combined with lipids and / or one or more of the other compounds described herein. For example, in certain variations, the liposomes further comprise at least one phosphatidylcholine or phosphatidylethanolamine. In other variations, the liposomes further comprise polyethylene glycol conjugated to at least one lipid comprising at least one phospholipid. In certain variations, the liposomes further comprise cholesterol. In one variation, the liposome composition comprises: DSPC / DSPE-PEG / RH-DHPE, or DSPC / DSPE-PEG / RH-DHPE / Chol, or DSPC / Chol / DSPE-PEG / DOTAP / RH-DHPE.
[0114] In some embodiments, the liposome has formula (B): [ka] (In the formula: each R b are independently carbon chains, and R c is an optionally substituted amino group or a quaternary ammonium substituted carbon chain, or a salt thereof. b is a saturated carbon chain. In another embodiment, each R bis an unsaturated carbon chain. In some embodiments, each R b is C 10~28 In certain embodiments, R c -C 1~6 Alkyl-N(CH 3 ) 2 In another embodiment, R c teeth, [ka] -C replaced with 1~6 In some embodiments, the at least one compound of formula (B) is 1,2-dioleoyl-3-dimethylammonium-propane (DODAP) or a salt thereof. In some embodiments, the at least one compound of formula (B) is [ka] or a salt thereof. In certain embodiments, the at least one compound of formula (B) is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or a salt thereof. In some embodiments, the at least one compound of formula (B) is: [ka] or a salt thereof.
[0115] In some embodiments of the above aspect, the liposomes comprising at least one compound of formula (B) may be combined with one or more of the lipids and other compounds described herein. For example, in certain variations, the liposomes further comprise at least one phosphatidylcholine or phosphatidylethanolamine. In other variations, the liposomes further comprise polyethylene glycol conjugated to at least one lipid, including at least one phospholipid. In certain variations, the liposomes further comprise cholesterol. In one variation, the liposome composition comprises DSPC / Chol / DSPE-PEG / DOTAP / RH-DHPE.
[0116] In some embodiments, the liposome has formula (C): [ka] (In the formula, R d is a carbon chain substituted with an optionally substituted amino group, and each R e and R are independently a carbon chain, or a salt thereof. d is C substituted with a substituted amino group 1~6 In certain embodiments, R d -C 1~6 Alkyl-N(alkyl) 2 In certain embodiments, R d -C 1~6 Alkyl-N(CH 3 ) 2 In certain embodiments, R d -CH 2 CH 2 N(CH 3 ) 2 In another embodiment, R d Ha-CH 2 CH 2 CH 2 N(CH 3 ) 2 In some embodiments, each R e is a saturated carbon chain. In another embodiment, each R e is an unsaturated carbon chain. In some embodiments, each R e C 10~28 alkenyl. In some embodiments, at least one compound of formula (C) is Dlin-KC2-DMA. In some embodiments, at least one compound of formula (C) is 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane or a salt thereof. In certain embodiments, at least one compound of formula (C) is [ka] or a salt thereof. In other embodiments, at least one compound of formula (C) is Dlin-KC3-DMA. In some embodiments, at least one compound of formula (C) is 2,2-dilinoleyl-4-dimethylaminopropyl-[1,3]-dioxolane or a salt thereof. In certain variations, at least one compound of formula (C) is [ka] or a salt thereof.
[0117] In some embodiments of the above aspect, the liposomes comprising at least one compound of formula (C) may be combined with one or more of the lipids and other compounds described herein. For example, in certain variations, the liposomes further comprise at least one phosphatidylcholine or phosphatidylethanolamine. In other variations, the liposomes further comprise polyethylene glycol conjugated to at least one lipid, including at least one phospholipid. In certain variations, the liposomes further comprise cholesterol. In one variation, the liposome composition comprises DSPC / DMG-PEG / Dlin-KC2-DMA / Chol.
[0118] In some embodiments, the liposome has formula (D): [ka] (In the formula, each R f are independently an optionally substituted carbon chain, or two R f or salts thereof. f may independently be one or more -OC(O)-C 10~28 C optionally substituted with alkyl 1~6 In another embodiment, two R attached to the same N atom are alkyl. f together form a six-membered ring, which is 1~6Alkyl-substituted, C 1~6 The alkyl is further optionally substituted. In one embodiment, at least one compound of formula (D) is ssPalmm, which corresponds to bis{2-{N-methyl-N-(tetradecanoylpropyl)amino]ethyl} disulfide or a salt thereof. In one embodiment, at least one compound of formula (D) is [ka] or a salt thereof. In another embodiment, the at least one compound of formula (D) is ssPalme, which corresponds to bis{2-[4-(α-D-tocopherol hemisuccinate ethyl) piperidyl] ethyl} disulfide or a salt thereof. In one embodiment, the at least one compound of formula (D) is [ka] or a salt thereof.
[0119] In some embodiments of the above aspect, the liposomes comprising at least one compound of formula (D) may be combined with one or more of the lipids and other compounds described herein. For example, in certain variations, the liposomes further comprise at least one phosphatidylcholine or phosphatidylethanolamine. In other variations, the liposomes further comprise polyethylene glycol conjugated to at least one lipid, including at least one phospholipid. In certain variations, the liposomes further comprise cholesterol. In one variation, the liposome composition comprises ssPalmm / SOPC / PEG(2k)-DSG / Chol; or ssPalme / SOPC / PEG(2k)-DSG / Chol.
[0120] In another aspect, the present invention relates to a compound of formula (PL-2A): [ka] (In the formula: T 2a and T 2beach of which is a carbon chain; R 2 In some embodiments, a composition is provided that includes a liposome comprising a phospholipid of T 2a and T 2b is independently a saturated or unsaturated carbon chain. In one particular variation, the quaternary ammonium is -N + (Alkyl) 3 In one variation of the foregoing, the alkyl is independently C1-6 alkyl, or C1-4 alkyl, or methyl, ethyl, or propyl. In one variation, the phospholipid of formula (PL-2A) is 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) or a salt thereof. In one variation, the phospholipid of formula (PL-2A) is [ka] or a salt thereof.
[0121] In some embodiments of the above aspect, the liposomes comprising at least one phospholipid of formula (PL-2A) may be combined with one or more of the lipids and other compounds described herein. For example, in certain variations, the liposomes further comprise at least one phosphatidylcholine or phosphatidylethanolamine. In other variations, the liposomes further comprise polyethylene glycol conjugated to at least one lipid, including at least one phospholipid. In certain variations, the liposomes further comprise cholesterol. In one variation, the liposome composition comprises ssPalmm / SOPC / PEG(2k)-DSG / Chol; or ssPalme / SOPC / PEG(2k)-DSG / Chol.
[0122] In one embodiment, the liposome comprises at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail being at least one C 10~28In some embodiments, the at least one phospholipid has an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail having at least one C 10~28 The phospholipid comprising the carbon chain is 1,2-distearoyl-sn-glycero-3-phosphocholine. In some embodiments, the liposome further comprises at least one PEGylated phospholipid. In some embodiments, the at least one PEGylated phospholipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine. In other embodiments, the at least one PEGylated lipid is 1,2-dimyristoyl-glycerol (DMG). In some embodiments, the liposome further comprises a phospholipid having the formula (A), as defined above: [ka] or a salt thereof. In some embodiments, the at least one compound of formula (A) is [ka] or a salt thereof. In some embodiments, the liposome further comprises at least one sterol. In certain embodiments, the at least one sterol is cholesterol. In certain embodiments, the liposome further comprises a sterol having formula (B) as defined above: [ka] or a salt thereof. In some embodiments, the at least one compound of formula (B) is 1,2-dioleoyl-3-dimethylammonium-propane (DODAP) or a salt thereof. In certain embodiments, the at least one compound of formula (B) is [ka] or a salt thereof. In another embodiment, the liposome composition further comprises a compound represented by formula (C): [ka] or a salt thereof. In some embodiments, at least one compound of formula (C) is Dlin-KC2-DMA. In other embodiments, at least one compound of formula (C) is Dlin-KC3-DMA. In certain embodiments, at least one compound of formula (C) is [ka] or a salt thereof. In another embodiment, at least one compound of formula (C) is [ka] or a salt thereof.
[0123] In one aspect, the present invention relates to a compound of formula (D), as defined above: [ka] or a salt thereof. In some embodiments, the at least one compound of formula (D) is bis{2-{N-methyl-N-(tetradecanoylpropyl)amino]ethyl}disulfide or a salt thereof. In one embodiment, the at least one compound of formula (D) is [ka] or a salt thereof. In another embodiment, the at least one compound of formula (D) is ssPalme, which corresponds to bis{2-[4-(α-D-tocopherol hemisuccinate ethyl) piperidyl]ethyl} disulfide or a salt thereof. In one embodiment, the at least one compound of formula (D) is [ka] or a salt thereof. In some embodiments, the liposome further comprises at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail being at least one C 10~28In some embodiments, the at least one phospholipid has an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail having at least one C 10~28 The phospholipid comprising a carbon chain is 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC). In some embodiments, the liposome further comprises at least one PEGylated phospholipid. In some embodiments, the at least one PEGylated phospholipid is 1,2-diastearoylglycerol (DSG). In some embodiments, the at least one PEGylated phospholipid is PEG(2k)-DSG. In some embodiments, the liposome further comprises at least one sterol. In certain embodiments, the at least one sterol is cholesterol.
[0124] In one aspect, the present disclosure provides a method for the preparation of a glycerol-based glycerol derivative comprising administering to a subject a glycerol-based glycerol derivative, a choline-based glycerol derivative, a phosphate-based glycerol derivative, and a serine-based glycerol derivative, comprising administering to a subject a glycerol-based glycerol derivative, a choline-based glycerol derivative, a phosphate-based glycerol derivative, and a serine- 10~28 In some embodiments, the liposome composition comprises one or more phospholipids having a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine, and a fatty acid tail comprising an aliphatic chain. 10~28 In some embodiments, the one or more phospholipids having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail having at least one C 10~28 In some embodiments, the present invention comprises at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail comprising at least one C 10~28The phospholipid comprising a carbon chain is 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). In some embodiments, the liposome further comprises at least one PEGylated phospholipid. In some embodiments, the at least one PEGylated phospholipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine. In some embodiments, the liposome further comprises at least one sterol. In certain embodiments, the at least one sterol is cholesterol.
[0125] In one aspect: DSPC / DSPE-PEG / RH-DHPE, DSPC / DSPE-PEG / RH-DHPE / Chol, DSPC / DODAP / DSPE-PEG / Chol, DSPC / DMG-PEG / Dlin-KC2-DMA / Chol, ssPalmm / SOPC / PEG(2k)-DSG / Chol, ssPalme / SOPC / PEG(2k)-DSG / Chol, DSPA / DOPC / DSPE-PEG / Chol, N-C12-DOPE / DOPC, N-C12-DOPE / DOPC / DSPE-PEG, N-C12-DOPE / DOPC / DSPE-PEG / Chol, N-C12-DOPE / DPPE / DOPC / DSPE-PEG, N-C12-DOPE / DOPE / DOPC / DSPE-PEG, DOPE / DOPG / DSPE-PEG, DOPE / DSPA / DSPE-PEG, DOPE / DC-Chol / DSPE-PEG, DOPE / DOPC / DSPE-PEG, DOPE / DPPG / DOPC / DSPE-PEG, DOPE / DOPC / DSPE-PEG / Chol, DOPE / DOPS / DSPE-PEG, DOPE / CHEMS, DOPE / CHEMS / DSPE-PEG, DOPE / CHEMS / DSPE-PEG / Chol, DOPE / CHEMS / DOPC / DSPE-PEG, or a salt thereof, or any combination of the foregoing. A liposome composition is provided comprising:
[0126] In some variations of the foregoing, PEG may be present in the liposomes with a molecular weight ranging from about 200 Da to about 40,000 Da. In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure with a molecular weight ranging from about 200 Da to about 10,000 Da. In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure with a molecular weight ranging from about 200 Da to about 10,000 Da. In some embodiments, polyethylene glycol (PEG) may be present in the liposomes of the present disclosure with a molecular weight ranging from about 200 Da to about 300 Da, about 400 Da, about 500 Da, about 600 Da, about 700 Da, about 800 Da, about 900 Da, about 1,000 Da, about 1,500 Da, about 2,000 Da, about 2,500 Da, about 3,000 Da, about 3,500 Da, about 4,000 Da, about 4,500 Da. a, about 5,000 Da, about 5,500 Da, about 6,000 Da, about 6,500 Da, about 7,000 Da, about 7,500 Da, about 8,000 Da, about 8,500 Da, about 9,000 Da, about 9,500 Da, or about 10,000 Da; or between about 200 Da and about 10,000 Da.
[0127] In some variations of the foregoing, lipids, including phospholipids, described herein may be present in the liposome composition in a salt form. For example, in one variation, the phospholipid is DOPE or a salt thereof. carbohydrates
[0128] Another aspect of the present disclosure relates to compositions containing carbohydrates encapsulated in the liposomes of the present disclosure. Any suitable carbohydrate known in the art may be used. Suitable carbohydrates that may be used include, for example, monosaccharides, phosphorylated monosaccharides, disaccharides, phosphorylated disaccharides, oligosaccharides, phosphorylated oligosaccharides, polysaccharides, phosphorylated polysaccharides, nucleotide sugars, endogenous carbohydrates, and phosphorylated endogenous carbohydrates. In some embodiments, the carbohydrate is an endogenous carbohydrate. In some variations, the carbohydrate is a phosphorylated carbohydrate.
[0129] In some embodiments, the phosphorylated carbohydrates of the present disclosure are endogenous carbohydrates. In some embodiments, endogenous carbohydrates are carbohydrates found as natural products in a subject (including, for example, a human). However, it should be understood that endogenous carbohydrates may be (i) naturally produced by a subject (including, for example, a human) and extracted from living cells of such a subject; or (ii) synthetically produced. In some embodiments, endogenous carbohydrates are produced in vivo by a subject (including, for example, a human). In other embodiments, endogenous carbohydrates are naturally produced by cells derived from a subject (including, for example, a human), such as a cultured cell line. Thus, sources of such endogenous carbohydrates may include, for example, synthetic sources (e.g., chemical synthesis) or natural sources (e.g., extracted, isolated, or purified from a subject or cell that naturally produces endogenous carbohydrates, or from recombinant cells, such as bacterial cells, that have been genetically modified to produce endogenous carbohydrates). Endogenous carbohydrates may include, for example, carbohydrates involved in protein and lipid glycosylation.
[0130] Suitable endogenous carbohydrates include, for example, monosaccharides, phosphorylated monosaccharides, disaccharides, phosphorylated disaccharides, oligosaccharides, phosphorylated oligosaccharides, polysaccharides, phosphorylated polysaccharides, mannose, phosphorylated mannose, mannofuranose, phosphorylated mannofuranose, mannopyranose, phosphorylated mannopyranose, mannose-1-phosphate, mannose-6-phosphate, nucleotide sugars, uridine diphosphate, guanine diphosphate, cytosine monophosphate, fucose, GDP-fucose, sialic acid, CMP-sialic acid, N-acetylneuraminic acid (Neu5Ac), and CMP-Neu5Ac. In one variation, the carbohydrate is mannose-1-phosphate, also referred to herein as "M1P."
[0131] In some embodiments, the carbohydrate is a phosphorylated endogenous carbohydrate. In some embodiments, the phosphorylated endogenous carbohydrate comprises, for example, a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. In some embodiments, the phosphorylated endogenous carbohydrate is a phosphorylated monosaccharide. In some embodiments, the phosphorylated endogenous carbohydrate is mannose-1-phosphate. In some embodiments, the phosphorylated endogenous carbohydrate is mannose-6-phosphate.
[0132] In some variations of the foregoing embodiments, any of the carbohydrates listed herein may be present in the liposome composition in a salt form, for example, in one variation, the phosphorylated carbohydrate is mannose-1-phosphate or a salt thereof. Liposome compositions encapsulating carbohydrates
[0133] Any of the liposomes described herein can be used to encapsulate a carbohydrate in a liposomal composition. Any of the carbohydrates described herein can be encapsulated in a liposome within the liposomal composition.
[0134] In one aspect, provided herein: A liposome comprising: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a salt thereof; ii) (a) a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine; and C 10~28 and one or more phospholipids having a fatty acid tail that includes an aliphatic chain; or (b) an acidic cholesterol ester, or a mixture of (a) and (b); one or more stabilizers selected from: iii) PEG conjugated to at least one phospholipid. A liposome comprising At least one endogenous phosphorylated carbohydrate encapsulated in a liposome; A composition comprising:
[0135] In another aspect, the present disclosure provides A liposome comprising: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b at least one of the carbon chains is unsaturated; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b each of which is an unsaturated carbon chain; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2substituted alkyl) or a salt thereof; [ka] (In the formula: T 3a and T 3b each of which is a saturated carbon chain; G 3 is H, or alkyl substituted with at least one -OH, or a salt thereof ; and [ka]
[0136] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0137] In another aspect, herein: A liposome comprising: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b at least one of the carbon chains is unsaturated; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b each of which is an unsaturated carbon chain; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2 or a salt thereof [ka] (In the formula: T 3a and T 3b each of which is a carbon chain; G 3 is H, or alkyl substituted with at least one -OH), or a salt thereof; and [ka]
[0138] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0139] In another aspect, herein: A liposome comprising: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE) or a salt thereof; ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or a salt thereof and a liposome comprising: At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0140] In another aspect, herein: A liposome comprising: i) [ka] or salts thereof; ii) [ka] or its salt and a liposome comprising: At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0141] In another aspect, provided herein is a liposome comprising: Formula (PL-4): [ka] (In the formula: T 1a and T 1b at least one of R is an unsaturated carbon chain; 4 is an aliphatic chain containing an amide moiety), or a salt thereof and a liposome comprising: At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising:
[0142] At least one phosphorylated endogenous carbohydrate of the compositions described herein may be present at a concentration of about 0.1-75 mM, about 0.1-0.5 mM, about 0.1-40 mM, about 0.1-30 mM, about 0.1-20 mM, about 0.1-10 mM, about 0.5-1.0 mM, about 1.0-1.5 mM, about 1.5-2.0 mM, about 2.0-2.5 mM, about 2.5-3.0 mM, about 3.0-3.5 mM, about 3.5-4.0 mM, about 4.0-4.5 mM, , about 4.5-5.0 mM, about 5.0-7.5 mM, about 7.5-10 mM, about 10-15 mM, about 15-20 mM, about 20-30 mM, about 30-40 mM, about 40-50 mM, about 50-75 mM, about 0.1-2.5 mM, about 2.5-5.0 mM, about 5.0-10 mM, about 10-25 mM, about 25-50 mM, about 50-75 mM, about 0.1-10 mM, about 10-30 mM, or about 30-75 mM. Pharmaceutical Compositions
[0143] The compositions of the present disclosure, containing liposomes of the present disclosure and phosphorylated carbohydrates of the present disclosure encapsulated in the liposomes, can be incorporated into a variety of formulations, for example, formulated into preparations in liquid, aerosolized, semi-solid, or in powder form, for use in therapy (e.g., by administration) or in the manufacture of a medicament (e.g., for delivering the carbohydrates of the present disclosure to a subject in need thereof and / or inside the cells of a subject in need thereof, and / or for treating or preventing a disease or disorder such as congenital glycosylation disorders (CDGs) in a subject in need thereof), by combining the compositions with a suitable carrier (e.g., including a pharma- ceutically acceptable carrier or diluent), and may be formulated into a preparation in liquid, aerosolized, semi-solid, or in powder form.
[0144] In some embodiments, the carrier comprises a pharma- ceutically acceptable carrier, excipient, or stabilizer that is non-toxic to cells or subjects exposed thereto at the dosage and concentration used. Often, the physiologically acceptable carrier is an aqueous pH buffered solution. Suitable physiologically acceptable carriers include, for example, buffers such as phosphate, citric acid, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or non-ionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®. In certain embodiments where the physiologically acceptable carrier is a salt forming counterion such as sodium, the sodium ion is present in solution along with other ions including, for example, chloride. In certain embodiments, the physiologically acceptable carrier comprises saline. In some embodiments, the saline is present in an amount of 0-200 mM. In other embodiments, the saline is present in an amount of 0-175 mM. In yet other embodiments, the saline is present in an amount of 0-150 mM.
[0145] In other embodiments, the pharma- ceutically acceptable carrier is glycerol, xylitol, sucrose, trehalose, polysorbate 80, alanine, proline, taurine, betaine, octopine, histidine, calcium citrate, ammonium sulfate, urea, or cetylmethyl-ammonium.
[0146] Suitable formulations include, for example, solutions, injections, inhalants, microspheres, aerosols, gels, ointments, creams, lotions, powders, dry vesicle powders, tablets, and capsules. The pharmaceutical composition may include a pharma- ceutically acceptable non-toxic carrier of a diluent, which is a vehicle commonly used to formulate pharmaceutical compositions for administration to animals or humans, depending on the desired formulation. The diluent is selected so as not to affect the biological activity of the combination. Such diluents include, for example, distilled water, buffered water, saline, phosphate-buffered saline (PBS), Ringer's solution, dextrose solution, and Hank's solution. The pharmaceutical composition or formulation of the present disclosure may further include, for example, other carriers, or non-toxic non-therapeutic, non-immunogenic stabilizers and excipients. The composition may also include additional substances to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, wetting agents, and detergents. The pharmaceutical composition of the present disclosure may also include any of a variety of stabilizers, such as, for example, antioxidants.
[0147] For oral administration, the active ingredient can be administered in solid dosage forms such as capsules, tablets, and powders, or in liquid dosage forms such as elixirs, syrups, and suspensions. The active ingredient can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate. Examples of additional inactive ingredients that may be added to obtain desired color, taste, stability, buffering capacity, dispersion or other known desired characteristics are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to continuously release the medicine over a period of hours. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated to selectively disintegrate in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
[0148] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents, solubilizing agents, thickening agents, stabilizing agents, and preservatives.
[0149] The components used to formulate pharmaceutical compositions are preferably of high purity and substantially free of potentially harmful contaminants (e.g., at least National Food (NF) grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Furthermore, compositions intended for in vivo use are usually sterile. To the extent that a given compound must be synthesized prior to use, the resulting product is typically substantially free of any potentially toxic agents, particularly any endotoxins that may be present during the synthesis or purification process. Compositions for parenteral administration are also sterile, substantially isotonic, and made under GMP conditions. Drug Dosage
[0150] Pharmaceutical compositions of the present disclosure, including compositions containing liposomes of the present disclosure and carbohydrates of the present disclosure encapsulated by liposomes, may be used (e.g., administered to a subject in need of treatment with a carbohydrate of the present disclosure, such as a human individual) according to known methods, such as by oral administration, intravenous administration over a period of time, as a bolus or by continuous infusion, intramuscular, intraperitoneal, intracerebrospinal, intracranial, intrathecal, subcutaneous, intra-articular, intrasynovial, intraspinal, oral, topical, or inhalation routes.
[0151] The dosage and desired concentration of the pharmaceutical composition of the present disclosure may vary depending on the specific use envisaged. The determination of the appropriate dosage or route of administration is well within the scope of those skilled in the art. Animal experiments provide reliable guidance for determining the effective dose for human treatment. Interspecies scaling of effective dose can be performed according to the principles described in Mordenti, J. and Chappell, W. "The Use of Interspecies Scaling in Toxicokinetics," Toxicokinetics and New Drug Development, Yacobi et al., Eds, Pergamon Press, New York 1989, pp.42-46.
[0152] For in vivo administration of any of the compositions of the present disclosure, including the liposomes of the present disclosure and the carbohydrates of the present disclosure encapsulated in liposomes, typical dosages may vary from 10 ng / kg to 100 mg / kg of the subject's body weight per day.
[0153] Administration of compositions of the present disclosure containing liposomes of the present disclosure and liposome-encapsulated carbohydrates of the present disclosure, whether the purpose of administration is therapeutic or prophylactic, can be continuous or intermittent, depending, for example, on the physical condition of the recipient, and other factors known to the skilled practitioner.
[0154] It is within the scope of this disclosure that different formulations are effective for different treatments and different disorders, and that administration intended to treat a certain organ or tissue may require delivery in a different manner than that intended for another organ or tissue.Furthermore, dosage may be administered by one or more separate administrations, or by continuous infusion.In the case of repeated administrations over several days or longer periods, depending on the condition, treatment is sustained until the desired suppression of disease symptoms occurs.However, other dosing regimens may be used.The progress of this treatment is easily monitored by conventional techniques and assays.
[0155] Thus, in some variations, the compositions provided herein may be administered chronically or intermittently to a subject (including, for example, a human) in need thereof. In certain variations, chronic administration is the administration of a pharmaceutical agent(s) on a continuous basis, as opposed to an acute form, such that the initial therapeutic effect (activity) is maintained over an extended period of time. In certain variations, intermittent administration is a treatment that is not administered continuously without interruption, but rather is cyclical in nature. Manufacturing method
[0156] In certain aspects, the present invention provides a method for producing the liposome composition described herein.In certain embodiments, the method includes: a) dissolving lipid in a solvent to produce a mixture; b) drying the mixture to form a thin film; c) hydrating the thin film with an aqueous solution that comprises phosphorylated carbohydrate; d) heating the solution of step c) to resuspend the thin film, thereby producing a suspension; and e) subjecting the suspension to at least one freeze-thaw cycle to produce the liposome composition.In some variations, the method further includes: adjusting the size of the liposome composition by sonication, extrusion, or microfluidization, or any combination thereof.
[0157] In some variations of the above, the method further comprises adjusting the pH of the liposome composition, hi other variations, the method further comprises removing unencapsulated phosphorylated carbohydrate by dialysis, solid phase extraction, or tangential flow filtration.
[0158] In one embodiment, the lipid components of liposomes are dissolved in chloroform, and the resulting mixture is heated to completely dissolve lipids. The mixture is then dried into a thin film coating, for example, on a flask or tube. The thin film is then hydrated with a solution containing mannose-1-phosphate, and the resulting suspension is heated, vortexed, and sonicated to produce a complete suspension of lipids. The liposome suspension is then subjected to a freeze-thaw cycle, followed by sizing, for example, using: sonication, extrusion, or microfluidization. In some variations, the pH of the solution is adjusted and / or unencapsulated mannose-1-phosphate is removed from the formulation using techniques such as dialysis, solid phase extraction, or tangential flow filtration. therapeutic use
[0159] The present disclosure provides compositions containing liposomes of the present disclosure and phosphorylated carbohydrates of the present disclosure encapsulated in liposomes capable of delivering carbohydrates to the interior of a cell, which compositions are useful for delivering phosphorylated carbohydrates of the present disclosure to a subject in need of such carbohydrates.
[0160] In some embodiments, the subject is a mammal, such as a human, a domestic animal such as a feline or canine subject, a farm animal (e.g., a cow, a horse, a goat, a sheep, and a pig subject), a wild animal (whether in the wild or in a zoo), a laboratory animal such as a mouse, a rat, a rabbit, a goat, a sheep, a pig, a dog, and a cat, and a bird. In one embodiment, the subject is a human.
[0161] In some variations, the subject may be at risk. For example, in one variation, the subject is a human at risk. A subject at risk of developing a particular disease, disorder, or condition, such as a congenital glycosylation disorder, may or may not have detectable disease or disease symptoms, and may or may not show detectable disease or disease symptoms prior to the treatment methods described herein. In certain variations, an "at risk" individual is an individual who has risk factors that are measurable parameters that correlate with the development of a particular disease, disorder, or condition known in the art. A subject who has one or more of these risk factors has a higher chance of developing a particular disease, disorder, or condition, such as a congenital glycosylation disorder, than a subject who does not have one or more of these risk factors.
[0162] In some embodiments, congenital glycosylation disorders (CDGs) are a group of genetic disorders that result in deficient or defective glycosylation of various tissue proteins and / or lipids, leading to metabolic errors. Congenital glycosylation disorders may also be known as CDG syndromes. CDG syndromes often cause severe, sometimes fatal, dysfunction of several different organ systems, such as the nervous system, brain, muscles, and intestines, in affected infants. Symptoms of CDG syndromes may range from severe growth retardation and hypotonia beginning in infancy to hypoglycemia and protein-losing enteropathy with normal development. Growth retardation may be a common early sign in CDG diagnosis. One of the most common subtypes of CDG syndrome is CDG-Ia (also known as PMM2-CDG), in which a genetic defect results in the loss of phosphomannomutase 2, the enzyme responsible for the conversion of mannose-6-phosphate to mannose-1-phosphate.
[0163] CDG syndrome can be classified as type I (CDG-I) and type II (CDG-II). Such classification may depend on the nature and location of the biochemical defect in the metabolic pathway relative to the action of oligosaccharyltransferase. Methods for screening CDG subtypes may include analysis of transferrin glycosylation status, for example by isoelectric focusing or ESI-MS. CDG type I includes, for example, Ia (PMM2-CDG), Ib (MPI-CDG), Ic (ALG6-CDG), Id (ALG3-CDG), Ie (DPM1-CDG), If (MPDU1-CDG), Ig (ALG12-CDG), Ih (ALG8-CDG), Ii (ALG2-CDG), Ij (DPAGT1-CDG), Ik (ALG1-CDG), 1L (ALG9-CDG), Im (DOLK-CDG), In (RFT1-CDG), Io (DPM3-CDG), Ip (ALG11-CDG), Iq (SRD5A3-CDG), Ir (DDOST-CDG), DPM2-CDG, TUSC3-CDG, MAGT1-CDG, DHDDS-CDG, and I / IIx. CDG type II includes, for example, IIa (MGAT2-CDG), IIb (GCS1-CDG), IIc (SLC335C1-CDG), IId (B4GALT1-CDG), IIe (COG7-CDG), IIf (SLC35A1-CDG), IIg (COG1-CDG), IIh (COG8-CDG), IIi (COG5-CDG), IIj (COG4-CDG), IIL (COG6-CDG), ATP6V0A2-CDG, MAN1B1-CDG, and ST3GAL3-CDG.
[0164] Congenital glycosylation disorders (CDGs) that may be treated with the disclosed compositions containing the disclosed liposomes and liposome-encapsulated carbohydrates of the present disclosure include, for example, Ia (PMM2-CDG), Ib (MPI-CDG), Ic (ALG6-CDG), Id (ALG3-CDG), Ie (DPM1-CDG), If (MPDU1-CDG), Ig (ALG12-CDG), Ih (ALG8-CDG), Ii (ALG2-CDG), Ij (DPAGT1-CDG), Ik (ALG1-CDG), 1L (ALG9-CDG), Im (DOLK-CDG), In (RFT1-CDG), Io (DPM3-CDG), Ip (ALG11-CDG), and Ip (ALG12-CDG). G), Iq(SRD5A3-CDG), Ir(DDOST-CDG), DPM2-CDG, TUSC3-CDG, MAGT1-CDG, DHDDS-CDG, I / IIx, IIa(MGAT2-CDG), IIb(GCS1-CDG), IIc(SLC335C1-CDG), IId(B4GALT1-CDG), IIe(COG7-CDG), IIf(SLC35A1-CDG), IIg(COG1-CDG), IIh(COG8-CDG), IIi(COG5-CDG), IIj(COG4-CDG), IIL(COG6-CDG), ATP6V0A2-CDG, MAN1B1-CDG, and ST3GAL3-CDG.
[0165] In some embodiments, "treatment" or "treating" includes an approach to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting a disease or condition (e.g., reducing one or more symptoms resulting from a disease or condition and / or reducing the severity of the disease or condition); b) slowing or halting the onset of one or more clinical symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or slowing the progression or worsening of a disease or condition, and / or preventing or slowing the spread of a disease or condition); and / or c) palliating a disease, i.e., causing a regression of clinical symptoms (e.g., improving a disease state, providing partial or total remission of a disease or condition, enhancing the effect of another medication, slowing the progression of a disease, increasing quality of life, and / or prolonging survival).
[0166] In some embodiments, "prevention" or "preventing" includes any treatment of a disease or condition that does not result in the clinical symptoms of the disease or condition. The compounds may, in some embodiments, be administered to subjects (including humans) at risk for or with a family history of the disease or condition.
[0167] In some variations, an "effective amount" is an amount effective, at least at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result. An effective amount can be provided in one or more administrations.
[0168] In some variations, a "therapeutically effective amount" is at least the minimum concentration required to effect a measurable improvement of a particular disease, disorder, or condition, such as a congenital glycosylation disorder. The therapeutically effective amount herein may vary depending on factors such as the disease state, age, sex, and weight of the subject, as well as the ability of the lipid composition of the present disclosure to elicit a desired response in the subject. A therapeutically effective amount is also an amount in which any toxic or adverse effects of the lipid composition of the present disclosure are outweighed by the therapeutically beneficial effects.
[0169] In one aspect, provided herein is a method for delivering phosphorylated carbohydrates to a subject in need thereof. In some embodiments, the method comprises administering to the subject any of the compositions described herein.
[0170] In another aspect, provided herein is a method for delivering phosphorylated carbohydrates to the interior of a cell in a subject in need thereof. In some embodiments, the method comprises administering to the subject any of the compositions described herein. In some embodiments, at least a portion of the administered composition crosses the cell plasma membrane to deliver the carbohydrate to the interior of the cell.
[0171] In another aspect, provided herein is a method for treating congenital glycosylation disorders (CDGs) in a subject in need thereof. In some embodiments, the method comprises administering any of the compositions described herein to the subject. In some embodiments, the congenital glycosylation disorder (CDG) is a CDG-Ia disorder. In some embodiments, administration of the composition induces a 0.05-fold to at least 3-fold increase in cellular production of higher order lipid-linked oligosaccharides in a human compared to cellular production of higher order lipid-linked oligosaccharides in the human in the absence of administration of the composition to the subject. Manufactured Products and Kits
[0172] The present disclosure also provides articles of manufacture and / or kits containing compositions of the present disclosure containing liposomes of the present disclosure and carbohydrates encapsulated by liposomes of the present disclosure. The articles of manufacture and / or kits of the present disclosure may include one or more containers containing the purified compositions of the present disclosure. Suitable containers may include, for example, bottles, vials, syringes, and IV solution bags. The containers may be formed from a variety of materials, such as glass or plastic. In some embodiments, the articles of manufacture and / or kits further include instructions for use with any of the methods of the present disclosure. In some embodiments, these instructions include instructions for administering compositions containing liposomes of the present disclosure and carbohydrates encapsulated by liposomes of the present disclosure to a subject in need thereof, to deliver carbohydrates to a cell of a subject in need thereof, or to treat congenital glycosylation disorders (CDGs) in a subject in need thereof, according to any of the methods of the present disclosure. In some embodiments, the instructions include instructions on how to detect congenital glycosylation disorders (CDGs), for example, in a subject, in a tissue sample, or in a cell. The article of manufacture and / or kit may further include instructions for selecting subjects suitable for treatment based on identifying whether or not the subject has the disease and stage of the disease.
[0173] The instructions generally include information regarding dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit dose, bulk packages (e.g., multi-dose packages), or sub-unit doses. Instructions provided with the articles of manufacture and / or kits of the present disclosure are typically written instructions on a label or insert (e.g., a paper included in the article of manufacture and / or kit), although machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
[0174] The label or package insert indicates that the composition is used for delivering carbohydrates and / or for treating, for example, congenital glycosylation disorders (CDGs). Instructions for use may be provided for practicing any of the methods described herein.
[0175] The article of manufacture and / or kit of the present disclosure may be in suitable packaging. Suitable packaging includes, for example, vials, bottles, jars, and flexible packaging (e.g., sealed Mylar or plastic bags). Packages used in combination with specific devices, such as inhalers, intranasal administration devices (e.g., atomizers), or infusion devices such as mini-pumps, are also contemplated. The article of manufacture and / or kit may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). The container may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is a carbohydrate capable of treating congenital glycosylation disorders (CDG) and / or ameliorating one or more symptoms thereof. The container may further include a second medicamentously active agent.
[0176] The article of manufacture and / or kit may optionally provide additional components, such as buffers and instructional information. Typically, the article of manufacture and / or kit comprises a container and a label or package insert on or associated with the container. Enumerated Embodiments
[0177] The embodiments listed below are representative of some aspects of the present invention. 1. A liposome comprising: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); ii) (a) a polar head group selected from the group consisting of glycerol, choline, phosphate, and serine; and C10~28 one or more phospholipids having a fatty acid tail that includes an aliphatic chain; and (b) acidic cholesterol esters, or a mixture of (a) and (b). one or more stabilizers selected from the group consisting of: iii) PEG conjugated to at least one phospholipid. A liposome comprising At least one endogenous phosphorylated carbohydrate encapsulated in a liposome; A composition comprising: 2. The composition of embodiment 1, wherein the liposome further comprises cholesterol. 3. The composition of embodiment 2, wherein cholesterol is present in an amount up to 25 mol %. 4. The composition of any one of embodiments 1-3, wherein at least one endogenous phosphorylated carbohydrate is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. 5. The composition of any one of embodiments 1-4, wherein at least one endogenous phosphorylated carbohydrate is phosphorylated mannose. 6. The composition of embodiment 5, wherein the phosphorylated mannose is mannose-1-phosphate. 7. The composition of any one of embodiments 1-6, wherein the endogenous phosphorylated carbohydrate is present at a concentration of about 0.1-75 mM. 8. The composition of any one of embodiments 1-7, wherein DOPE is present in a concentration of up to 80 mol %. 9. The composition of any one of embodiments 1-8, wherein the one or more stabilizers comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 10. The composition of any one of embodiments 1-8, wherein the one or more stabilizers comprise 1,2-dipalmitoyl-phosphatidyl-glycerol (DPPG). 11. The composition of any one of embodiments 1-8, wherein the one or more stabilizers comprise 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG). 12. The composition of any one of embodiments 1-8, wherein the one or more stabilizers comprise 1,2-distearoyl-sn-glycero-3-phosphate (DSPA). 13. The composition of any one of embodiments 1-8, wherein the one or more stabilizers comprise 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS). 14. The composition of any one of embodiments 1-13, wherein the one or more stabilizers are present in an amount up to 70 mol %. 15. The composition of any one of embodiments 1-14, wherein at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). 16. The composition of embodiment 15, wherein the PEG-DSPE is present in a concentration of up to 5 mol %. 17. A liposome comprising: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE); ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising: 18. The composition of embodiment 17, wherein at least one endogenous phosphorylated carbohydrate is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. 19. The composition of embodiment 17 or embodiment 18, wherein at least one endogenous phosphorylated carbohydrate is phosphorylated mannose. 20. The composition of embodiment 19, wherein the phosphorylated mannose is mannose-1-phosphate. 21. The composition of any one of embodiments 17-20, wherein the endogenous phosphorylated carbohydrate is present at a concentration of about 0.1 to 75 mM. 22. The composition of any one of embodiments 17-21, wherein N-C12-DOPE is present in an amount up to 80 mol %. 23. The composition of any one of embodiments 17-22, wherein DOPC is present in an amount up to 30 mol %. 24. The composition of any one of embodiments 17-23, wherein the liposome further comprises PEG conjugated to at least one phospholipid. 25. The composition of embodiment 24, wherein at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). 26. The composition of embodiment 25, wherein the PEG-DSPE is present in a concentration of up to 5 mol %. 27. The composition of any one of embodiments 17-26, wherein the liposome further comprises cholesterol. 28. The composition of embodiment 27, wherein cholesterol is present in an amount up to 25 mol %. 29. A liposome comprising: i) at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail, the unsaturated fatty acid tail comprising at least one C10-28 carbon chain; ii) (a) to (c): a) at least one phospholipid having a polar head group and a saturated fatty acid tail; b) at least one phospholipid having a polar head group and an unsaturated fatty acid tail, the polar head group comprising a quaternary ammonium cation, a glycerol group, or a serine group; and c) at least one acidic cholesterol ester one or more of; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising: 30. The composition of embodiment 29, wherein the unsaturated fatty acid tail of at least one phospholipid in i) contains at least one double bond. 31. The composition of embodiment 29 or embodiment 30, wherein the unsaturated fatty acid tail of at least one phospholipid in i) contains one double bond. 32. The composition of any one of embodiments 29-31, wherein the unsaturated fatty acid tail comprises at least one C16-20 carbon chain. 33. The composition of any one of embodiments 29-32, wherein the phospholipid having an ethanolamine head group and a fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). 34. The composition of any one of embodiments 29 to 33, wherein the saturated fatty acid tail of at least one phospholipid in a) comprises at least a C16-20 carbon chain. 35. The composition of any one of embodiments 29 to 34, wherein at least one phospholipid having a polar head group and an unsaturated fatty acid tail is 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol (DPPG) or 1,2-distearoyl-sn-glycero-3-phosphate (DSPA) or both. 36. The composition of any one of embodiments 29 to 35, wherein the polar head group of at least one phospholipid in b) is choline. 37. The composition of any one of embodiments 29 to 36, wherein at least one phospholipid having a polar head group with a quaternary ammonium cation and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 38. The composition of any one of embodiments 29 to 35, wherein the polar head group of at least one phospholipid in b) is serine. 39. The composition of embodiment 38, wherein at least one phospholipid having a polar head group with a serine group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS). 40. The composition of any one of embodiments 29 to 35, wherein the polar head group of at least one phospholipid in b) is glycerol. 41. The composition of embodiment 40, wherein at least one phospholipid having a polar head group with a glycerol group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG). 42. The composition of any one of embodiments 29-41, wherein at least one acid cholesterol ester is cholesteryl hemisuccinate (CHEMS). 43. The composition of any one of embodiments 29-42, wherein at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). 44. The composition of any one of embodiments 29-43, wherein at least one phospholipid having an ethanolamine head group and an unsaturated fatty acid tail is present in a concentration of up to 50 mol %. 45. The composition of any one of embodiments 29-44, wherein one or more of (a) through (c) are present in a concentration of up to 70 mol %. 46. The composition of any one of embodiments 29-45, wherein the PEG conjugated to at least one phospholipid is present in a concentration of up to 5 mol %. 47. The composition of any one of embodiments 29-45, wherein the PEG conjugated to at least one phospholipid is present in a concentration of up to 3 mol %. 48. The composition of any one of embodiments 29 to 47, wherein at least one endogenous phosphorylated carbohydrate is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. 49. The composition of embodiments 29-48, wherein at least one endogenous phosphorylated carbohydrate is phosphorylated mannose. 50. The composition of embodiment 49, wherein the phosphorylated mannose is mannose-1-phosphate. 51. The composition of any one of embodiments 29 to 50, wherein the endogenous phosphorylated carbohydrate is present at a concentration of about 0.1 to 75 mM. 52. The composition of any one of embodiments 29 to 51, wherein the liposome further comprises cholesterol. 53. The composition of embodiment 52, wherein cholesterol is present in an amount up to 25 mol %. 54. A liposome comprising: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b At least one of the following is C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b Each of the C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2 substituted alkyl) or a salt thereof; [ka] (In the formula: T 3a and T 3b each of which is a saturated carbon chain; G 3 is H, or alkyl substituted with at least one -OH), or a salt thereof; and [ka] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising: 55. T 1a , T 1b , T 2a , and T 2b The composition of embodiment 54, wherein each of is independently an unsaturated carbon chain containing one double bond. 56. The composition of embodiment 55, wherein the unsaturated carbon chain is a cis isomer. 57. The composition of any one of embodiments 54-56, wherein each carbon chain has 10 to 28 carbon atoms. 58. The composition of embodiment 54, wherein at least one phospholipid of formula (PL-1) is DOPE. 59. The composition of embodiment 54 or embodiment 58, wherein at least one phospholipid of formula (PL-2) is DOPC or DOPS. 60. The composition of embodiment 54, 58, or 59, wherein at least one phospholipid of formula (PL-3) is DPPG, DOPG, or DSPA. 61. The composition of any one of embodiments 54-60, wherein at least one cholesterol ester of formula (CE) is CHEMS. 62. The composition of any one of embodiments 51-61, wherein the liposome further comprises cholesterol. 63. The composition of embodiment 62, wherein cholesterol is present in an amount up to 25 mol %. 64. The composition of any one of embodiments 51-63, wherein at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). 65. The composition of embodiment 64, wherein the PEG-DSPE is present in a concentration of up to 5 mol%. 66. A liposome comprising: Formula (PL-4): [ka] (In the formula: T 1a and T 1b At least one of the following is C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 4 is an aliphatic chain containing an amide moiety), or a salt thereof A liposome comprising At least one phosphorylated endogenous carbohydrate encapsulated in a liposome; A composition comprising: 67. The composition of embodiment 66, wherein PL-4 is N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (N-C12-DOPE). 68. The composition of embodiment 66 or embodiment 67, wherein at least one endogenous phosphorylated carbohydrate is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. 69. The composition of embodiment 66, wherein at least one endogenous phosphorylated carbohydrate is phosphorylated mannose. 70. The composition of embodiment 69, wherein the phosphorylated mannose is mannose-1-phosphate. 71. The composition of any one of embodiments 66-70, wherein the endogenous phosphorylated carbohydrate is present at a concentration of about 0.1 to 75 mM. 72. A pharmaceutical composition comprising the composition of any one of the preceding embodiments and a pharma- ceutically acceptable carrier. 73. A method for delivering carbohydrates to a human in need thereof, comprising administering to the human a composition of any one of the preceding embodiments. 74. A method for delivering carbohydrates to the interior of a cell in a subject in need thereof, comprising administering to the subject a composition of any one of embodiments 1 to 71 or a pharmaceutical composition of embodiment 72, wherein at least a portion of the administered composition crosses the cell plasma membrane to deliver the carbohydrate to the interior of the cell. 75. A method for treating congenital glycosylation disorders (CDGs) in a human in need thereof, comprising administering to the human a composition of any one of embodiments 1 to 71 or a pharmaceutical composition of embodiment 72. 76. The method of embodiment 75, wherein the congenital glycosylation disorder (CDG) is CDG-Ia disorder. 77. The method of embodiment 76, wherein administration of the composition induces a 0.05-fold to at least a 3-fold increase in cellular production of higher-order lipid-linked oligosaccharides in a human compared to cellular production of higher-order lipid-linked oligosaccharides in the human in the absence of administration of the composition to the human. 78. A kit comprising the composition of any one of embodiments 1 to 71 or the pharmaceutical composition of embodiment 72. 79. The kit of embodiment 78, further comprising a container, and a label or package insert on or associated with the container. 80. A liposome comprising: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine or a salt thereof; and ii) (a) Polar head groups including glycerol, choline, phosphate, and serine; and C 10~28 and a fatty acid tail comprising an aliphatic chain; or (b) acidic cholesterol esters, or both (a) and (b); and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one endogenous carbohydrate encapsulated in the liposome; A composition comprising: 81. One or more phospholipids having a polar head group are: 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-phosphatidyl-glycerol; 1,2-dioleoyl-sn-glycero-3-phosphoglycerol; 1,2-distearoyl-sn-glycero-3-phosphate; or 1,2-dioleoyl-sn-glycero-3-phospho-L-serine, or a salt thereof, or any combination of the above The composition of embodiment 80, comprising: 82. The composition of embodiment 81, wherein the one or more phospholipids having a polar head group comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof. 83. A liposome comprising: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine, or a salt thereof; and ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof A liposome comprising At least one endogenous carbohydrate encapsulated in the liposome; A composition comprising: 84. The composition of embodiment 83, wherein the liposome further comprises PEG conjugated to at least one phospholipid. 85. A liposome comprising: i) at least one phospholipid having an ethanolamine head group and at least one unsaturated fatty acid tail, each unsaturated fatty acid tail independently having at least one C 10~28 at least one phospholipid containing a carbon chain; ii) (a) to (c): a) at least one phospholipid having a polar head group and at least one saturated fatty acid tail; b) at least one phospholipid having a polar head group and at least one unsaturated fatty acid tail, the polar head group comprising a quaternary ammonium cation, a glycerol group, or a serine group; and c) at least one acidic cholesterol ester one or more of; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one endogenous carbohydrate encapsulated in the liposome; A composition comprising: 86. The composition of embodiment 85, wherein each unsaturated fatty acid tail of the at least one phospholipid in i) contains at least one double bond. 87. The composition of embodiment 85 or 86, wherein each unsaturated fatty acid tail of at least one phospholipid in i) contains one double bond. 88. The unsaturated fatty acid tail contains at least one C 16~20 The composition of any one of embodiments 85-87, comprising a carbon chain. 89. The composition of any one of embodiments 85-88, wherein the phospholipid having an ethanolamine head group and at least one unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine or a salt thereof. 90. The saturated fatty acid tail of at least one phospholipid in a) is at least C 16~20 The composition of any one of embodiments 85-89, comprising a carbon chain. 91. The composition of any one of embodiments 85 to 90, wherein at least one phospholipid having a polar head group and a saturated fatty acid tail is 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol, or 1,2-distearoyl-sn-glycero-3-phosphate, or a salt thereof, or a combination of the foregoing. 92. The composition of any one of embodiments 85-91, wherein the polar head group of at least one phospholipid in b) is choline. 93. The composition of embodiment 92, wherein at least one phospholipid having a polar head group with a quaternary ammonium cation and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof. 94. The composition of any one of embodiments 85-91, wherein the polar head group of at least one phospholipid in b) is serine. 95. The composition of embodiment 94, wherein at least one phospholipid having a polar head group with a serine group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phospho-L-serine or a salt thereof. 96. The composition of any one of embodiments 85-91, wherein the polar head group of at least one phospholipid in b) is glycerol. 97. The composition of embodiment 96, wherein at least one phospholipid having a polar head group with a glycerol group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoglycerol or a salt thereof. 98. The composition of any one of embodiments 85-97, wherein at least one acid cholesterol ester is cholesteryl hemisuccinate. 99. The composition of any one of embodiments 80-82 or 84-98, wherein at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine or a salt thereof. 100. A liposome comprising: i) Formula (PL-1): [ka] (In the formula: T 1a and T 1b At least one of the following is C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 1 is aminoalkyl), or a salt thereof; ii) at least one phospholipid of formula (PL-2), at least one phospholipid of formula (PL-3A), or at least one cholesterol ester of formula (CE): [ka] (In the formula: T 2a and T 2b Each of the C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 2 is an alkyl group substituted with quaternary ammonium, glycerol, or -COOH and -NH 2 substituted alkyl) or a salt thereof; [ka] (In the formula: T 3a and T 3b each of which is a carbon chain; G 3 is H, or alkyl substituted with at least one -OH), or a salt thereof; and [ka] (In the formula: Z 1 is alkyl substituted with -COOH) or a salt thereof, or any combination of the foregoing; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising At least one endogenous carbohydrate encapsulated in the liposome; A composition comprising: 101. T 1a , T 1b , T 2a , and T 2b The composition of embodiment 100, wherein each of is independently an unsaturated carbon chain containing one double bond. 102. The composition of embodiment 101, wherein the unsaturated carbon chain is a cis isomer. 103. The composition of any one of embodiments 100-102, wherein each carbon chain has 10 to 28 carbon atoms. 104. At least one phospholipid of formula (PL-1) [ka] or a salt thereof. 105. At least one phospholipid of formula (PL-2) [ka] or a salt thereof. 106. At least one phospholipid of formula (PL-3A) [ka] [ka] or a salt thereof. 107. At least one cholesterol ester of formula (CE) is [ka] or a salt thereof. 108. At least one phospholipid conjugated to PEG is [ka] The composition of any one of embodiments 80-82 and 84-107, wherein the compound is a tertiary amine, a tertiary amine, or a salt thereof. 109. A liposome comprising: Formula (PL-4): [ka] (In the formula: T 1a and T 1b At least one of the following is C 10~28 Alkenyl or C 10~28 is an unsaturated carbon chain containing alkynyl; R 4 is an aliphatic chain containing an amide moiety), or a salt thereof A liposome comprising At least one endogenous carbohydrate encapsulated in the liposome; A composition comprising: 110. PL-4, [ka] or a salt thereof. 111. At least one endogenous carbohydrate is: (i) endogenous phosphorylated carbohydrates; or (ii) The composition of any one of embodiments 80 to 110, which is a phosphorylated monosaccharide, a phosphorylated disaccharide, a phosphorylated oligosaccharide, a phosphorylated polysaccharide, a phosphorylated mannose, a phosphorylated mannofuranose, a phosphorylated mannopyranose, or a nucleotide sugar, or any combination thereof. 112. The composition of embodiment 111, wherein the phosphorylated mannose is mannose-1-phosphate. 113. A pharmaceutical composition comprising the composition of any one of the preceding embodiments and a pharma- ceutically acceptable carrier. 114. A method for delivering carbohydrates to a human in need thereof, comprising administering to the human a composition of any one of the preceding embodiments. 115. A method for delivering carbohydrates to the interior of a cell in a subject in need thereof, comprising administering to the subject a composition of any one of embodiments 1 to 113, wherein at least a portion of the administered composition crosses the cell plasma membrane and delivers the carbohydrate to the interior of the cell. 116. A method for treating congenital glycosylation disorders (CDGs) in a human in need thereof, comprising administering to the human a composition of any one of embodiments 1 to 113. 117. The method of embodiment 116, wherein the congenital glycosylation disorder (CDG) is a CDG-Ia disorder. 118. The method of embodiment 116 or 117, wherein administration of the composition induces a 0.05-fold to at least a 3-fold increase in cellular production of higher-order lipid-linked oligosaccharides in a human compared to cellular production of higher-order lipid-linked oligosaccharides in the human in the absence of administration of the composition to the human. 119. The composition of any one of embodiments 1 to 113; container; and A label or insert on or associated with a container Kit including: EXAMPLES
[0178] The following examples are illustrative only and are not intended to limit any aspect of the present disclosure in any way. Liposomes
[0179] Materials for liposome preparation were purchased from Avanti Polar Lipids, NOF America Corporation, FormuMax Scientific, Inc., CordenPharma, and Lipoid. The following lipids were purchased from Avanti: DOPE, DOPC, DPPG, DOPG, DOPS, N-C12-DOPE, Chol, CHEMS, and DSPE-PEG-Gal. The following lipids were purchased from NOF America Corporation: DSPA, DMG-PEG, ssPalmm, ssPalme, SOPC, and PEG(2k)-DSG. The following lipids were purchased from FormuMax Scientific, Inc.: RH-DHPE, DODAP, and DOTAP. The following lipids were purchased from CordenPharma: Dlink-KC2-DMA.
[0180] The lipid raw materials were dissolved in chloroform and warmed until completely dissolved. The mixture was then dried to form a thin film. The film was then hydrated with an aqueous solution containing phosphorylated carbohydrates. The solution was heated and mixed thoroughly to resuspend the thin film. The suspension was subjected to three freeze-thaw cycles. Finally, the size of the liposomes was adjusted by sonication, extrusion, or microfluidization. cell line
[0181] CDG-Ia human dermal fibroblasts and wild-type human dermal fibroblasts were purchased from the Coriell Institute. Culture medium
[0182] RPMI medium was mixed with FBS (10% v / v), Pen-Strep (1% v / v), and L-glutamine (1% v / v) to make complete RPMI medium. This medium was used to grow fibroblast cells. All of them were purchased from Thermo Fisher Scientific. Example 1 Screening and selection of lipids for intracellular delivery of M1P
[0183] To select the appropriate combination of lipids for intracellular delivery of M1P, different Lipo-M1P formulations were evaluated for their ability to penetrate cell membranes and promote endosomal escape and release M1P active components into the cytosol. A functional cell-based assay measuring GDP-mannose levels before and after treatment with Lipo-M1P was used as a measure of delivery and bioactivity of the various liposomal compositions. A total of 34 different Lipo-M1P formulations were prepared using a bench-scale thin film hydration method. Cells were treated with different Lipo-M1P formulations with total lipid concentrations up to 5.4 mM. Cell viability was determined using an XTT cell proliferation assay (Thermo Fisher Scientific), and 28 of the 33 formulations tested maintained cell viability higher than the desired 80%. After treatment, cells were harvested, GDP-mannose was extracted, and analyzed by liquid chromatography-mass spectroscopy (LC-MS). The results are summarized in Table 1. [Table 1-1] [Table 1-2] Example 2 Initial formulation stability study of Lipo-M1P
[0184] An in vitro assessment of M1P leakage from liposomes was performed to characterize the physical state of the lipid bilayer and encapsulated M1P and to gain an understanding of M1P stability within liposomes under physiological conditions. Freshly prepared Lipo-M1P particles were washed to remove free non-encapsulated M1P, after which Lipo-M1P was resuspended in PBS pH 7.4 and stored at 37°C. The liposome composition was DOPE:DOPC:DSPE-PEG2000=48.5:48.5:3 (mol%). At several time points up to 24 h, M1P leaked from the particles was isolated using a 10 kDa molecular weight cut-off membrane (MWCO) centrifugal filter, and the liposomes in the filter were brought up to the original volume by adding fresh PBS. The filtrate containing the leaked M1P was quantified by bicinchoninic acid assay (BCA assay). M1P leakage was calculated as % of total Lipo-M1P and plotted over time as shown in Figure 1. Negligible leakage was observed with only 2.5% released at 24 h, thus demonstrating that Lipo-M1P particles exhibit good stability in physiological buffers.
[0185] Figures 2A and 2B show the nanoparticle size distribution and concentration of micron-sized particles measured for Lipo-M1P in PBS pH 7.4 on days 2, 18, and 30 stored at 4°C. The number of micron-sized particles in the range of 2 to 5 microns measured on day 2 is 10^-7% of the total number of both nanometer and micron-sized particles. No significant change in particle size and distribution was observed between days 2 and 30, demonstrating that Lipo-M1P has a very limited tendency to aggregate during refrigerated storage. Data was collected using NanoSight and FlowCam particle imaging systems for the nanometer and micron size ranges, respectively.
[0186] Further stability data was collected on the aggregation of Lipo-M1P nanoparticles in 10% FBS, first incubated at 37° C. for 18 hours and then stored at 4° C. for 21 days. No shift in particle size distribution was observed between day 2 in PBS and day 21 in FBS (data not shown). A slight increase in the concentration of micron-sized particles was observed, but the overall low percentage, 10^-7%, remained unchanged. Example 3 In vitro study of Lipo-M1P bioactivity in PMM2-CDG fibroblasts
[0187] This example investigates the biological activity of various Lipo-M1P formulations in cultured fibroblasts derived from patients. Three Lipo-M1P formulations were used:
[0188] Formulation A: DOPE / DOPC / DSPE-PEG(2000)=58.2:38.8:3; Formulation B: N-C12-DOPE / DOPC / DSPE-PEG(2000)=69.6:27.4:3 Formulation C: DSPC / Chol / DSPE-PEG / DOTAP / Rh-DHPE=24:45:5:25:0.5
[0189] Patient-derived cultured fibroblasts were treated for 18 hours with Formulation A at concentrations ranging from 0.15 to 0.72 mM. Mass spectrometry analysis showing an increase in GDP-mannose over untreated patient and normal fibroblasts is shown in FIG. 3A. M1P metabolite levels were normalized to overnight treatment with a low dose of Lipo-M1P at approximately 0.35 mM. As expected, GDP-mannose increased with increasing concentrations of Lipo-M1P. Cell viability remained near 100% over the Lipo-M1P concentration range investigated, FIG. 3B.
[0190] To determine whether the decreased levels of full-length mature LLO could be corrected with formulation B, patient fibroblasts were incubated with Lipo-M1P at 0.24 mM for LLO studies and with Lipo-M1P at concentrations ranging between 0.06 and 0.48 mM for ICAM-1. After 18 hours of treatment, cells were harvested and LLO was extracted, labeled with a fluorescent tag, and examined by fluorophore-assisted carbohydrate electrophoresis (FACE). Qualitative results are displayed in Figure 4. Lipo-M1P treatment increased the levels of full-length LLO, indicating that the delivered M1P is metabolized to GDP-mannose and enters the LLO biosynthetic pathway.
[0191] To assess the impact of treatment on the levels of the protein biomarker intercellular adhesion molecule 1 (ICAM-1), ICAM-1 was extracted using the Mem-PER™ Plus membrane protein extraction kit (Thermo Fisher Scientific) and visualized by Western blot using an anti-ICAM-1 antibody (R&D). The results are presented in Figure 5. The concentration-dependent increase in ICAM-1 provides evidence that Formulation C restores the N-glycan biosynthetic pathway and corrects protein hypoglycosylation in the patient's cells. Example 4 Biodistribution and pharmacokinetics of Lipo-M1P in CD-1 mice
[0192] A study evaluating the pharmacokinetics of Lipo-M1P in female CD-1 mice was performed at Bayside Biosciences (Santa Clara, CA). Sixteen CD-1 female mice were injected with Oregon Green-labeled Lipo-M1P via tail vein injection at a dose of 250 mg / kg lipid and 12.5 mg / kg M1P. The composition of the liposomes was DOPE:DOPC:DSPE-PEG with a 1:1 (mol%) ratio of DOPE to DOPC. Mice were divided into four groups and one group was selected at each time point for blood collection or blood and liver collection at various time points up to 48 hours. The concentration of liposomes in plasma and homogenized liver was measured using the fluorescence of the Oregon Green label. The pharmacokinetic properties of Lipo-M1P are summarized in Table 2. [Table 2]
[0193] In addition to plasma PK, liposomal PK in the liver was assessed and is shown in Figure 6A. The elimination half-life in the liver was 6.22 hours. The intrahepatic distribution of Lipo-M1P was assessed to confirm delivery of Lipo-M1P to hepatocytes. Four CD-1 female mice were dosed with Oregon Green-labeled Lipo-M1P at 290 mg / kg lipid and 15 mg / kg M1P. Mice were sacrificed 1 hour after injection and livers were perfused and digested using liver digestion medium (Thermo Fisher Scientific). Hepatocytes and nonparenchymal cells (NPCs) were isolated from the digested liver suspension using Percoll density gradient centrifugation. Fluorescence from liposomes in hepatocytes and NPCs was measured using flow cytometry. Autofluorescence from cells was subtracted. Figure 6B shows that Lipo-M1P was preferentially taken up by hepatocytes, while no statistically significant uptake of Lipo-M1P into NPCs was observed.
[0194] The effect of PEGylation and the presence of galactose moieties on the surface of liposomes on the liver uptake of Lipo-M1P was thoroughly evaluated (data not shown). There was no significant difference in liver uptake between 3% and 5% PEG and a molecular weight of 2000 Da. Reducing the PEG length to 350 Da and increasing its percentage to 7.5% resulted in more than one-fold increased cellular uptake; however, the plasma half-life was significantly decreased. Galactose moieties did not significantly improve the hepatocyte targeting ability of liposomes in vitro or in vivo. Example 5 Safety and toxicity of Lipo-M1P in rats
[0195] Dose escalation and repeat dose studies in Sprague Dawley rats were performed at Charles River Laboratories. Animals were approximately 5 weeks old at the start of the study. Lipo-M1P was injected into the tail vein via intravenous (slow bolus) injection. In the dose escalation phase, four groups of three males received a single dose of Lipo-M1P (DOPE / DOPC / DSPE-PEG / M1P; lipid ratio: 48.5:48.5:3). Group 1 received 100 mg lipid per kg body weight, group 2 received 250 mg / kg, group 3 received 500 mg / kg, and group 4 received 652.8 mg / kg. The maximum M1P dose administered (group 4) was 47.1 mg / kg M1P. The dose in group 4 was in a maximum feasible dose volume of 10 ml / kg. A 24 hour observation period was maintained before proceeding to subsequent dosing groups. No clinical effects were observed at any concentration. One group of 3 females received the maximum dose of 652.8 mg / kg lipid. No clinical effects were observed. Blood was collected from all animals 7 days after dosing for clinical chemistry and hematology analysis. Small dose-dependent increases in both red blood cells and platelets were observed in males. The results are summarized in Table 3. Using a similar protocol, rats were dosed with Lipo-M1P (N-C12-DOPE / DOPC / DSPE-PEG / M1P; lipid ratio: 69.6:27.4:3), where the maximum feasible dose was 864.2 mg / kg (at a dose volume of 10 ml / kg, 86.42 mg / ml lipid), and no adverse clinical effects were observed at any dose. Clinical pathology results are summarized in Table 3. [Table 3] A repeat dose study was performed using Lipo-M1P at a lipid concentration of 62 mg / ml. One group of three males and three females each received a daily IV bolus injection of 620 mg / kg lipid (34.3 mg / kg M1P) for seven consecutive days. This dose was the maximum feasible dose volume of 10 ml / kg. No clinical effects were observed during the dosing phase. One day after the final dose administration, blood was collected for clinical chemistry and hematology analysis and necropsy was performed. No visible lesions were observed. Clinical pathology results are summarized in Tables 4 and 5. [Table 4] [Table 5]
[0196] A single dose escalation study in rats with Lipo-M1P up to 652.8 mg / kg (i.e., 47.1 mg / kg M1P) did not show any clinical effects. Repeated dosing of Lipo-M1P at 620 mg / kg (i.e., 34.3 mg / kg M1P) was then administered as a bolus injection daily for 7 days to 3 male and 3 female rats. No visible clinical symptoms or visible lesions were present at necropsy. Plasma cholesterol was increased in both males and females. The present invention provides, for example, the following items. (Item 1) A liposome comprising: i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine or a salt thereof; and ii) (a) Polar head groups including glycerol, choline, phosphate, and serine; and C 10~28 and a fatty acid tail comprising an aliphatic chain; or (b) acidic cholesterol esters, or both (a) and (b); and iii) a liposome comprising polyethylene glycol (PEG) conjugated to at least one phospholipid; at least one endogenous phosphorylated carbohydrate encapsulated in said liposome; A composition comprising: (Item 2) The one or more phospholipids having a polar head group are 1,2-dioleoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-phosphatidyl-glycerol; 1,2-dioleoyl-sn-glycero-3-phosphoglycerol; 1,2-distearoyl-sn-glycero-3-phosphate; or 1,2-dioleoyl-sn-glycero-3-phospho-L-serine, or a salt thereof, Or the composition according to item 1, comprising any combination of the above. (Item 3) 3. The composition of claim 2, wherein the one or more phospholipids having a polar head group comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof. (Item 4) A liposome comprising: i) N-dodecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine, or a salt thereof; and ii) 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof A liposome comprising at least one endogenous phosphorylated carbohydrate encapsulated in said liposome; A composition comprising: (Item 5) 5. The composition of claim 4, wherein the liposome further comprises PEG conjugated to at least one phospholipid. (Item 6) A liposome comprising: i) at least one phospholipid having an ethanolamine head group and at least one unsaturated fatty acid tail, each unsaturated fatty acid tail independently having at least one C 10~28 at least one phospholipid containing a carbon chain; ii) (a) to (c): a) at least one phospholipid having a polar head group and at least one saturated fatty acid tail; b) at least one phospholipid having a polar head group and at least one unsaturated fatty acid tail, the polar head group comprising a quaternary ammonium cation, a glycerol group, or a serine group; and c) at least one acidic cholesterol ester one or more of; and iii) Polyethylene glycol (PEG) conjugated to at least one phospholipid. A liposome comprising at least one endogenous phosphorylated carbohydrate encapsulated in said liposome; A composition comprising: (Item 7) 7. The composition of claim 6, wherein each unsaturated fatty acid tail of the at least one phospholipid in i) comprises at least one double bond. (Item 8) 8. The composition according to item 6 or 7, wherein each unsaturated fatty acid tail of the at least one phospholipid in i) contains one double bond. (Item 9) The unsaturated fatty acid tail comprises at least one C 16~20 9. The composition according to any one of items 6 to 8, comprising a carbon chain. (Item 10) 10. The composition of any one of items 6 to 9, wherein the phospholipid having an ethanolamine head group and at least one unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine or a salt thereof. (Item 11) The saturated fatty acid tail of the at least one phospholipid in a) is at least 16~20 11. The composition according to any one of items 6 to 10, comprising a carbon chain. (Item 12) 12. The composition according to any one of items 6 to 11, wherein the at least one phospholipid having a polar head group and a saturated fatty acid tail is 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol or 1,2-distearoyl-sn-glycero-3-phosphate, or a salt thereof, or a combination of the foregoing. (Item 13) 13. The composition according to any one of items 6 to 12, wherein the polar head group of the at least one phospholipid in b) is choline. (Item 14) 13. The composition according to any one of items 6 to 12, wherein the at least one phospholipid having a polar head group with a quaternary ammonium cation and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphocholine or a salt thereof. (Item 15) 13. The composition according to any one of items 6 to 12, wherein the polar head group of the at least one phospholipid in b) is serine. (Item 16) 13. The composition according to any one of items 6 to 12, wherein the at least one phospholipid having a polar head group with a serine group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phospho-L-serine or a salt thereof. (Item 17) 13. The composition according to any one of items 6 to 12, wherein the polar head group of the at least one phospholipid in b) is glycerol. (Item 18) 13. The composition according to any one of items 6 to 12, wherein the at least one phospholipid having a polar head group with a glycerol group and an unsaturated fatty acid tail is 1,2-dioleoyl-sn-glycero-3-phosphoglycerol or a salt thereof. (Item 19) 19. The composition according to any one of items 6 to 18, wherein the at least one acidic cholesterol ester is cholesteryl hemisuccinate. (Item 20) 20. The composition of any one of items 1 to 3 or 5 to 19, wherein the at least one phospholipid conjugated to PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine or a salt thereof. (Item 21) A liposome comprising: i) Formula (PL-1):
change
change
change
change
change
change
change
change
change
change
change
change
Claims
1. A composition comprising a liposome and mannose-1-phosphate or a salt thereof encapsulated in the liposome, The liposome is i) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a salt thereof; ii) one or more phospholipids having a polar head group comprising glycerol, choline, phosphate, or serine, and two unsaturated fatty acid tails, wherein each unsaturated fatty acid tail is selected from the group consisting of C 10~28 A phospholipid containing an alkenyl chain; and iii) A composition comprising polyethylene glycol (PEG) conjugated to at least one phospholipid.
2. 2. The composition of claim 1, wherein the polar head group of the one or more phospholipids in ii) is choline.
3. The one or more phospholipids having a polar head group are 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG); or 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or a salt thereof, or any combination of the foregoing.
4. 3. The composition of claim 2, wherein the one or more phospholipids having a polar head group comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or a salt thereof.
5. 5. The composition of claim 1, wherein the phospholipid conjugated to the PEG is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).
6. The component (iii) of the liposome is DSPE-PEG 2000 The composition according to any one of claims 1 to 4, wherein
7. The composition of claim 1 , wherein the liposome does not contain cholesterol or cholesterol esters.
8. The composition of any one of claims 1 to 4, wherein the DOPE is present in the composition at 15 to 30 mole percent.
9. 9. The composition of claim 8, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 35 to 75 mole percent.
10. 9. The composition of claim 8, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 60-65 mole percent.
11. The composition of any one of claims 1 to 4, wherein the DOPE is present in the composition at 25 to 30 mole percent.
12. 12. The composition of claim 11, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 35 to 75 mole percent.
13. 12. The composition of claim 11, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 60-65 mole percent.
14. The composition of any one of claims 1 to 4, wherein the DOPE is present in the composition at 30 to 60 mole percent.
15. 15. The composition of claim 14, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 35 to 75 mole percent.
16. 15. The composition of claim 14, wherein the one or more phospholipids having a polar head group is DOPC, and wherein the DOPC is present in the composition at 60-65 mole percent.
17. The composition according to any one of claims 1 to 16, wherein the concentration of mannose-1-phosphate in the liposome is from 2.5 mM to 5 mM.
18. The composition according to any one of claims 1 to 16, wherein the concentration of mannose-1-phosphate in the liposome is from 5 mM to 10 mM.
19. A liposome composition comprising mannose-1-phosphate or a salt thereof and a liposome, the liposome being selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and DSPE-PEG. 2000 wherein DOPE, DOPC and DSPE-PEG 2000 The molar ratio of said mannose-1-phosphate or a salt thereof is 30:67:3, and said mannose-1-phosphate or a salt thereof is encapsulated in said liposome.
20. 20. The composition of claim 1, wherein the liposomes in the composition have an average particle size of 0.1 microns ± 2%.
21. A pharmaceutical composition comprising the composition of any one of claims 1 to 20 and a pharma- ceutically acceptable carrier.
22. 22. The pharmaceutical composition of claim 21 for treating congenital glycosylation disorders (CDGs) in a human in need thereof.
23. The pharmaceutical composition of claim 22, wherein the CDG is CDG-Ia, CDG-Ie, CDG-Ii, CDG-Ik, CDG-Io, CDG-Ip, or DPM2-CDG.
Citation Information
Patent Citations
PEGylated liposomes for the delivery of immunogen-encoding RNA
JP2014525461A
Methods of using biomarkers for the treatment of cancer by modulating bcl2 expression
JP2016509572A
chimeric protein
JP2017537650A
Mannosyl-1 phosphates, preparation method and therapeutic use, in particular against the CDG-ia syndrome
US20090054353A1
Pharmaceutical preparation of carbohydrates for therapeutic use
US20160228364A1
